[{"pdf_link":"Study_338.pdf","index":0,"AA_Date":"2025-05-15","Drug_Name":"Zynyz (retifanlimab-dlwr)","Brand_Name":"Zynyz","Active_Ingredient":"retifanlimab-dlwr","Approved_Indication":"the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.","Company_name":"Incyte Corporation","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.","Full prescribing information for Zynyz will be posted on Drugs@FDA.","Efficacy of retifanlimab-dlwr with carboplatin and paclitaxel was evaluated in POD1UM-303\/InterAACT 2 (NCT04472429), a randomized, multicenter, double-blind trial in 308 patients with chemotherapy-na\u00efve inoperable locally recurrent or metastatic SCAC. Patients received carboplatin AUC of 5 on Day 1, and paclitaxel 80 mg\/m2 on Days 1, 8, and 15 for 6 cycles and were randomized (1:1) to receive either:","The major efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to RECIST v1.1. Overall survival (OS) was a key secondary endpoint. Additional efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) as assessed by BICR. Median PFS was 9.3 months (95% CI: 7.5, 11.3) in the retifanlimab-dlwr arm and 7.4 months (95% CI: 7.1, 7.7) in the placebo arm (hazard ratio 0.63 [95% CI: 0.47, 0.84] p-value 0.0006). Interim OS results were not statistically significant: median OS was 29.2 months (95% CI: 24.2, not estimable [NE]) and 23 months (95% CI: 15.1, 27.9) in the respective arms (hazard ratio 0.70 [95% CI: 0.49, 1.01]). Forty-five percent of patients who received placebo received retifanlimab-dlwr after disease progression. ORR was 56% (95% CI: 48, 64) and 44% (95% CI: 36, 52) in the respective arms.","Efficacy of retifanlimab-dlwr as a single agent was evaluated in POD1UM-202 (NCT03597295), an open-label, multicenter, single-arm trial in 94 patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Patients received retifanlimab-dlwr 500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months. The major efficacy outcome measures were ORR and DOR as assessed by an independent review committee (IRC) according to RECIST v1.1. ORR was 14% (95% CI: 8, 23) and median DOR was 9.5 months (95% CI: 4.4, not estimable [NE]).","The prescribing information for retifanlimab-dlwr includes warnings and precautions for severe and fatal immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.","The recommended retifanlimab-dlwr dose in combination with carboplatin and paclitaxel is 500 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 12 months. The recommended dose of retifanlimab-dlwr as a single agent is 500 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months. Refer to the prescribing information for carboplatin and paclitaxel for recommended dosing information in combination with retifanlimab.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","Retifanlimab-dlwr was granted orphan drug designation for the treatment of anal cancer and this application was granted fast track designation and priority review. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology. ","05\/15\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-retifanlimab-dlwr-carboplatin-and-paclitaxel-and-single-agent-squamous-cell-carcinoma"},{"pdf_link":"Study_339.pdf","index":0,"AA_Date":"2025-05-14","Drug_Name":"Emrelis (telisotuzumab vedotin-tllv)","Brand_Name":"Emrelis","Active_Ingredient":"telisotuzumab vedotin-tllv","Approved_Indication":"the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [\u226550% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.","Company_name":"AbbVie Inc.","Relevant Expedited Programs":"Accelerated Approval;Priority Review","Approval_Details":["On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [\u226550% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.","FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics) as a companion diagnostic test to aid in detecting c-Met protein overexpression in patients with non-squamous NSCLC who may be eligible for treatment with Emrelis.","Full prescribing information for Emrelis will be posted on Drugs@FDA.","Efficacy was evaluated in the LUMINOSITY study (NCT03539536), a multicenter, open label, multi-cohort trial. The trial included 84 patients with epidermal growth factor receptor (EGFR) wild-type, non-squamous NSCLC with high c-Met protein overexpression who had received prior systemic therapy.","The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR), determined by blinded independent central review (BICR) according to RECIST 1.1. ORR was 35% (95% CI: 24, 46) and median DOR was 7.2 months (95% CI: 4.2, 12).","In a pooled safety population, the most common adverse reactions (\u226520%) were peripheral neuropathy, fatigue, decreased appetite, and peripheral edema. The most common Grade 3 or 4 laboratory abnormalities (\u22652%) were decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin, and decreased calcium.","The recommended telisotuzumab vedotin-tllv dose is 1.9 mg\/kg (up to a maximum of 190 mg for patients \u2265100 kg), as an intravenous infusion every 2 weeks, until disease progression or unacceptable toxicity.","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review and breakthrough designation.  FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","05\/14\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression"},{"pdf_link":"Study_340.pdf","index":2,"AA_Date":"2025-05-14","Drug_Name":"Welireg (belzutifan)","Brand_Name":"Welireg","Active_Ingredient":"belzutifan","Approved_Indication":"the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.","Company_name":"Merck & Co., Inc.","Relevant Expedited Programs":"Priority Review","Approval_Details":["On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.","Full prescribing information for Welireg will be posted on Drugs@FDA.","Efficacy was evaluated in LITESPARK-015 (NCT04924075), an open-label, multi-cohort trial. Cohort A1 was conducted in 72 patients with measurable disease verified by blinded independent central review (BICR) per RECIST v1.1, documented histopathological PPGL diagnosis, and locally advanced or metastatic disease not amenable to surgery or curative treatment. Patients with concomitant hypertension with adequately controlled blood pressure were required to have no change in antihypertensive medications for at least 2 weeks prior to study initiation. Patients with carcinomatous meningitis were excluded.","The major efficacy outcome measure was objective response rate (ORR) by BICR using RECIST v1.1. Additional efficacy outcome measures were duration of response (DOR) and the number of patients who had a reduction in at least one antihypertensive medication by at least 50% maintained for at least six months. ORR was 26% (95% CI: 17, 38). Median DOR was 20.4 months (95% CI: 8.3, NR). Of the 60 patients on baseline antihypertensive medications, 19 (32% [95% CI: 20, 45]) had a reduction in at least one antihypertensive medication by at least 50% for at least six months.","The most common adverse reactions (\u226525%), including laboratory abnormalities, were anemia, fatigue, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, increased aspartate aminotransferase, increased calcium, dyspnea, increased potassium, decreased leukocytes, headache, increased alkaline phosphatase, dizziness, and nausea.","The recommended belzutifan dose for adults is 120 mg administered orally once daily. The recommended dose for pediatric patients 12 years and older is based on body weight. For pediatric patients weighing \u2265 40 kg, the dose is 120 mg orally once daily. For pediatric patients weighing < 40 kg, the dose is 80 mg orally once daily. Continue belzutifan until disease progression or unacceptable toxicity.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology. ","05\/14\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma"},{"pdf_link":"Study_341.pdf","index":1,"AA_Date":"2025-05-08","Drug_Name":"Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets)","Brand_Name":"Avmapki Fakzynja Co-Pack","Active_Ingredient":"avutometinib capsules; defactinib tablets","Approved_Indication":"the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.","Company_name":"Fakzynja Co-pack, Verastem, Inc.","Relevant Expedited Programs":"Accelerated Approval;Breakthrough Therapy Designation;Orphan Drug Designation;Priority Review","Approval_Details":["On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.","Full prescribing information for Avmapki Fakzynja Co-pack will be posted on Drugs@FDA.","Efficacy was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter trial that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. Patients were required to have received at least one prior systemic therapy, including a platinum-based regimen. KRAS mutation status was determined by prospective local testing of tumor tissue. Patients received avutometinib 3.2 mg orally twice weekly (Day 1 and Day 4) and defactinib 200 mg orally twice daily, both taken for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.","The major efficacy outcome measure was overall response rate (ORR) assessed by blinded independent review committee according to RECIST v1.1. An additional efficacy outcome measure was duration of response (DOR). Confirmed ORR was 44% (95% CI: 31, 58) and the DOR range was 3.3 months to 31.1 months.","The most common adverse reactions (\u226525%), including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.","The recommended avutometinib dose is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity. The recommended defactinib dose is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review. Avutometinib in combination with defactinib was granted breakthrough therapy designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology. ","05\/08\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"Ovarian cancer","Biomarker":"","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low"},{"pdf_link":"Study_338.pdf","index":3,"AA_Date":"2025-05-08","Drug_Name":"Avmapki Fakzynja Co-pack (the combination of avumetinib and defactinib)","Brand_Name":"Avmapki Fakzynja Co-pack","Active_Ingredient":"the combination of avumetinib and defactinib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.","Company_name":"Fakzynja Co-pack, Verastem, Inc.","Relevant Expedited Programs":"Accelerated Approval;Breakthrough Therapy Designation;Orphan Drug Designation;Priority Review","Approval_Details":["On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.","Full prescribing information for Avmapki Fakzynja Co-pack will be posted on Drugs@FDA.","Efficacy was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter trial that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. Patients were required to have received at least one prior systemic therapy, including a platinum-based regimen. KRAS mutation status was determined by prospective local testing of tumor tissue. Patients received avutometinib 3.2 mg orally twice weekly (Day 1 and Day 4) and defactinib 200 mg orally twice daily, both taken for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.","The major efficacy outcome measure was overall response rate (ORR) assessed by blinded independent review committee according to RECIST v1.1. An additional efficacy outcome measure was duration of response (DOR). Confirmed ORR was 44% (95% CI: 31, 58) and the DOR range was 3.3 months to 31.1 months.","The most common adverse reactions (\u226525%), including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.","The recommended avutometinib dose is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity. The recommended defactinib dose is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review. Avutometinib in combination with defactinib was granted breakthrough therapy designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology. ","05\/08\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"Ovarian cancer","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low"},{"pdf_link":"Study_109.pdf","index":4,"AA_Date":"2025-04-23","Drug_Name":"Akeso Biopharma Co. (penpulimab-kcqx)","Brand_Name":"Akeso Biopharma Co.","Active_Ingredient":"penpulimab-kcqx","Approved_Indication":"the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.","Company_name":"Biopharma Co., Ltd.","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation","Approval_Details":["On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.","Full prescribing information for penpulimab-kcqx will be posted on Drugs@FDA."],"Efficacy and Safety":["The primary efficacy outcome measure was progression-free survival (PFS), as assessed by a Blinded Independent Review Committee according to RECIST v1.1. Overall survival (OS) was a key secondary endpoint. Median PFS was 9.6 months (95% CI: 7.1, 12.5) in the penpulimab-kcqx arm and 7.0 months (95% CI: 6.9, 7.3) in the placebo arm (hazard ratio [HR] 0.45 [95% CI: 0.33, 0.62], two-sided p-value <0.0001), with 31% and 11% of patients alive and progression-free after 12 months of follow-up in the penpulimab-kcqx and placebo arms, respectively. While OS results were immature, with 70% of pre-specified deaths for the final analysis reported, no detrimental trend was observed.","Efficacy of single-agent penpulimab-kcqx was evaluated in Study AK105-202 (NCT03866967), an open-label, multicenter, single-arm trial conducted in a single country. The trial included a total of 125 patients with unresectable or metastatic non-keratinizing NPC who had disease progression after platinum-based chemotherapy and at least one other line of therapy. Patients received penpulimab-kcqx until disease progression or unacceptable toxicity, for a maximum of 24 months.","The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by an Independent Radiology Review Committee. The ORR was 28% (95% CI: 20, 37) and median DOR was not reached (95% CI: 9.2, not estimable).","Immune-mediated adverse reactions occurred with penpulimab-kcqx including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin adverse reactions. The most common adverse reactions (\u226520%) for penpulimab-kcqx with cisplatin or carboplatin and gemcitabine were nausea, vomiting, hypothyroidism, constipation, decreased appetite, decreased weight, cough, COVID-19 infection, fatigue, rash, and pyrexia. The most common adverse reactions (\u226520%) for single-agent penpulimab-kcqx were hypothyroidism and musculoskeletal pain. Fatal adverse reactions occurred in 1% of patients, including a case each of pneumonitis, septic shock, colitis, and hepatitis.","The recommended penpulimab-kcqx dose with cisplatin or carboplatin and gemcitabine is 200 mg every three weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. The recommended single-agent penpulimab-kcqx dose for previously treated NPC is 200 mg every two weeks until disease progression or unacceptable toxicity, for a maximum of 24 months.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Nasopharyngeal carcinoma (NPC)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma"},{"pdf_link":"Study_165.pdf","index":5,"AA_Date":"2025-04-11","Drug_Name":"Opdivo + Yervoy (nivolumab + ipilimumab)","Brand_Name":"Opdivo + Yervoy","Active_Ingredient":"nivolumab + ipilimumab","Approved_Indication":"the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).","Company_name":"Bristol Myers Squibb Company","Relevant Expedited Programs":"Orphan Drug Designation","Approval_Details":["On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).","Full prescribing information for Opdivo will be posted on Drugs@FDA."],"Efficacy and Safety":["The primary efficacy outcome measure was overall survival (OS) in all randomized patients. Overall response rate (ORR) based on RECIST 1.1 criteria, assessed by blinded independent central review, was an additional efficacy outcome measure. Median OS was 23.7 months (95% CI: 18.8, 29.4) in the nivolumab + ipilimumab arm and 20.6 months (95% CI: 17.5, 22.5) in the lenvatinib or sorafenib arm (Hazard Ratio 0.79 [95% CI: 0.65, 0.96] p-value <0.0180. ORR was 36.1% (95% CI: 31.0, 41.5) and 13.2% (95% CI: 9.8, 17.3) in the respective arms (p-value <0.0001).","The most common adverse reactions (>20%) were rash, pruritus, fatigue, and diarrhea.","The recommended nivolumab dose is 1 mg\/kg with ipilimumab 3 mg\/kg intravenously every three weeks for a maximum of four doses, followed by nivolumab 240 mg IV every 2 weeks or nivolumab 480 mg IV as a single agent every 4 weeks.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada and Switzerland\u2019s Swissmedic. The application reviews are ongoing at the other regulatory agencies.","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Hepatocellular carcinoma (HCC)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma"},{"pdf_link":"Study_186.pdf","index":6,"AA_Date":"2025-04-08","Drug_Name":"Opdivo + Yervoy (nivolumab + ipilimumab)","Brand_Name":"Opdivo + Yervoy","Active_Ingredient":"nivolumab + ipilimumab","Approved_Indication":"the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.","Company_name":"Bristol Myers Squibb Company","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.","Full prescribing information for Opdivo and Yervoy will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1 in patients with centrally confirmed MSI-H\/dMMR status in the following pre-specified settings:","The analysis of nivolumab + ipilimumab versus chemotherapy in the first line setting was conducted in 255 patients with centrally confirmed MSI-H\/dMMR status of 303 patients based on local testing. Median PFS was not reached (NR) (95% CI: 38.4, not estimable [NE]) in the nivolumab + ipilimumab arm and 5.8 months (95% CI: 4.4, 7.8) in the chemotherapy arm (Hazard ratio 0.21 [95% CI: 0.14, 0.32] p-value <0.0001). Comparative results of ORR and OS between arms were not available at the time of the interim PFS analysis due to statistical testing strategy.","The analysis of nivolumab + ipilimumab versus nivolumab (all lines) was conducted in 582 patients with centrally confirmed MSI-H\/dMMR status of 707 patients based on local testing. Median PFS was NR (95% CI: 53.8, NE) in the nivolumab + ipilimumab arm and 39.3 months (95% CI: 22.1, NE) in the nivolumab arm (Hazard ratio 0.62 [95% CI: 0.48, 0.81] p-value 0.0003). ORR was 71% (95% CI: 65, 76) in the nivolumab + ipilimumab arm and 58% (95% CI: 52, 63) in the nivolumab arm (p-value 0.0011). The comparative results of OS between arms were not available at the interim PFS analysis due to statistical testing strategy.","The most common adverse reactions reported in \u226520% of patients treated with nivolumab with ipilimumab were fatigue, diarrhea, pruritus, abdominal pain, musculoskeletal pain, and nausea. The most common adverse reactions reported in \u226520% of patients treated with nivolumab as a single agent were fatigue, diarrhea, abdominal pain, pruritis, and musculoskeletal pain.","See the prescribing information for the recommended doses of nivolumab and ipilimumab.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Brazilian Health Regulatory Agency (ANVISA), the Israel Ministry of Health (IMoH), and Health Canada (HC). The application reviews are ongoing at the other regulatory agencies."],"Broad_Tumor":"Colorectal cancer (CRC)","Biomarker":"Mismatch repair deficient, Microsatellite instability-high (MSI-H) or Mismatch repair deficient (dMMR), Microsatellite instability-high (MSI-H), Microsatellite instability, Mismatch repair deficient (dMMR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer"},{"pdf_link":"Study_58.pdf","index":8,"AA_Date":"2025-03-28","Drug_Name":"Pluvicto (for lutetium Lu 177 vipivotide tetraxetan)","Brand_Name":"Pluvicto","Active_Ingredient":"for lutetium Lu 177 vipivotide tetraxetan","Approved_Indication":"the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.","Company_name":"Novartis Pharmaceuticals Corporation","Relevant Expedited Programs":"","Approval_Details":["On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.","Patients with previously treated mCRPC should be selected for Pluvicto using Locametz (active ingredient gallium Ga 68 gozetotide) or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors.","Full prescribing information for Pluvicto will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome was radiographic progression-free survival (rPFS) by blinded independent central review. Overall survival (OS) was an additional efficacy outcome. Median rPFS was 9.3 months (95% confidence interval [CI]: 7, not estimable) in the lutetium Lu 177 vipivotide tetraxetan arm and 5.6 months (95% CI: 4, 6) in the ARPI arm (hazard ratio [HR] 0.41 [95% CI: 0.29, 0.56]; p-value <0.0001). Median OS was 24.5 months (95% CI: 19.5, 28.9) and 23.1 months (95% CI: 19.6, 25.5) in the respective arms (HR 0.91 [95% CI: 0.72, 1.14]; p-value was not statistically significant). Sixty percent (n=141) of patients who were randomized to receive a change in ARPI crossed over to receive lutetium Lu 177 vipivotide tetraxetan after progression.","Adverse reactions were consistent with prior experience with lutetium Lu 177 vipivotide tetraxetan. Treatment with lutetium Lu 177 vipivotide tetraxetan may result in risk from radiation exposure, myelosuppression, and renal toxicity.","The recommended lutetium Lu 177 vipivotide tetraxetan dose is 7.4 GBq (200 mCi) intravenously every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity. \u00a0","This review used the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Prostate cancer","Biomarker":"Androgen Receptor, Prostate-specific membrane antigen (PSMA), Prostate-specific membrane antigen","url_name":"\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"},{"pdf_link":"Study_336.pdf","index":7,"AA_Date":"2025-03-28","Drug_Name":"Imfinzi (durvalumab)","Brand_Name":"Imfinzi","Active_Ingredient":"durvalumab","Approved_Indication":"the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).","Company_name":"AstraZeneca","Relevant Expedited Programs":"Priority Review","Approval_Details":["On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).","Full prescribing information for Imfinzi will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome was event-free survival (EFS) by blinded independent central review. Overall survival (OS) was an additional efficacy outcome. At a pre-specified interim analysis, the trial demonstrated a statistically significant improvement in EFS and OS. Median EFS was not reached (NR) (95% CI: NR, NR) in the durvalumab with chemotherapy arm and 46.1 months (95% CI: 32.2, NR) in the chemotherapy arm (hazard ratio 0.68 [95% CI: 0.56, 0.82]; two-sided p-value <0.0001). Median OS was not reached in either arm (hazard ratio 0.75 [95% CI: 0.59, 0.93]; two-sided p-value=0.0106).","Adverse reactions were consistent with prior experience with durvalumab with platinum-based chemotherapy.","The recommended durvalumab dose for patients with a body weight of \u226530 kg is 1,500 mg every 3 weeks with chemotherapy (neoadjuvant treatment) and 1,500 mg as a single agent every 4 weeks (adjuvant treatment). The recommended durvalumab dose for patients with a body weight <30 kg is 20 mg\/kg with chemotherapy every 3 weeks (neoadjuvant treatment) and 20 mg\/kg as a single agent every 4 weeks (adjuvant treatment). Treatment should continue until disease progression that precludes definitive surgery, recurrence, or unacceptable toxicity or a maximum of 8 cycles after surgery.","This review used the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-muscle-invasive-bladder-cancer"},{"pdf_link":"Study_173.pdf","index":9,"AA_Date":"2025-03-26","Drug_Name":"Cabometyx (cabozantinib)","Brand_Name":"Cabometyx","Active_Ingredient":"cabozantinib","Approved_Indication":"the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).","Company_name":"Exelixis, Inc.","Relevant Expedited Programs":"","Approval_Details":["On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).","Full prescribing information for Cabometyx will be posted here.","Efficacy of cabozantinib for patients with NETs was evaluated in CABINET (NCT03375320), a double-blind, placebo-controlled, multicenter trial with two separate, randomized cohorts (pNET and epNET) of 298 patients with unresectable, locally advanced, or metastatic pNET that had progressed on prior therapy.","In both cohorts, the major efficacy outcome measure was progression-free survival (PFS), assessed by blinded independent radiology review committee (BIRC) per RECIST 1.1. Additional efficacy outcome measures included overall response rate (ORR) and overall survival (OS).","The pNET cohort included 99 patients randomized (2:1) to receive cabozantinib 60 mg orally once daily or placebo until disease progression or unacceptable toxicity. Median PFS was 13.8 months (95% CI: 8.9, 17.0) in the cabozantinib arm and 3.3 months (95% CI: 2.8, 5.7) in the placebo arm (Hazard Ratio [HR] 0.22 [95% CI: 0.12, 0.41]; p-value <0.0001). ORR was 18% (95% CI: 10, 30) and 0 (95% CI: 0, 11) in the respective arms. OS data were not mature with 32 (48% of patients enrolled) deaths in the cabozantinib arm and 17 (52% of patients enrolled) deaths in the placebo arm (HR 1.01 [95% CI: 0.55, 1.83]). Fifty-two percent of placebo arm patients crossed over to open label cabozantinib, which may potentially impact the evaluation of OS.","The epNET cohort included 199 patients randomized (2:1) to receive the above regimen of cabozantinib or placebo until disease progression or unacceptable toxicity. Median PFS was 8.5 months (95% CI: 6.8, 12.5) in the cabozantinib arm and 4.2 months (95% CI: 3.0, 5.7) in the placebo arm (HR 0.40 [95% CI: 0.26, 0.61]; p-value <0.0001). ORR was 5% (95% CI: 2.2, 11) and 0 (95% CI: 0, 5) in the respective arms. OS data were not mature with 83 (63% of patients enrolled) deaths in the cabozantinib arm and 40 (60% of patients enrolled) in the placebo arm (HR 1.05 [95% CI: 0.71, 1.54]). Thirty-seven percent of those receiving placebo crossed over to open label cabozantinib, which may potentially impact the evaluation of OS.","The safety profile for cabozantinib was consistent with the approved product label.","The recommended cabozantinib dose for adult and pediatric patients 12 years and older with a bodyweight \u2265 40 kg is 60 mg orally once daily until disease progression or unacceptable toxicity. The recommended dose for pediatric patients 12 years and older with a bodyweight less than 40 kg is 40 mg orally once daily until disease progression or unacceptable toxicity.","This review was conducted under\u202fProject Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA) and Switzerland\u2019s Swissmedic. The application reviews are ongoing at the other regulatory agencies.","This review used rolling review and\u202fthe Assessment Aid, a submission from the applicant to facilitate the FDA\u2019s assessment.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s\u202fMedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X (formerly Twitter)\u202f@FDAOncology.","03\/26\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet"},{"pdf_link":"Study_144.pdf","index":10,"AA_Date":"2025-03-19","Drug_Name":"Keytruda (pembrolizumab)","Brand_Name":"Keytruda","Active_Ingredient":"pembrolizumab","Approved_Indication":"the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \u22651).","Company_name":"Merck","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation","Approval_Details":["On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \u22651).","Pembrolizumab previously received accelerated approval for this indication on May 5, 2021, based on interim analysis of the trial described below.","Full prescribing information for Keytruda will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measures assessed in patients were progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS). Additional outcome measures included overall response rate (ORR) and duration of response (DOR). A statistically significant improvement in OS and PFS was demonstrated in patients randomized to pembrolizumab in combination with trastuzumab and chemotherapy compared with placebo in combination with trastuzumab and chemotherapy. In patients with tumors that were PDL1 CPS\u22651, median PFS was 10.9 months (95% CI: 8.5, 12.5) in the pembrolizumab arm and 7.3 months (95% CI: 6.8, 8.4) in the placebo arm (Hazard ratio [HR] 0.72 [95% CI: 0.60, 0.87]). Median OS was 20.1 months (95% CI: 17.9, 22.9) and 15.7 months (95% CI: 13.5, 18.5) in the respective arms (HR 0.79 [95% CI: 0.66, 0.95]. ORR was 73% (95% CI: 68, 78) and 58% (95% CI: 53, 64) and median DOR was 11.3 months (95% CI: 9.9, 13.7) and 9.6 months (95% CI: 7.1, 11.2).","The adverse reaction profile observed in patients receiving pembrolizumab was consistent with the known pembrolizumab safety profile.","The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks in combination with trastuzumab and chemotherapy.","This review used the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Gastric or gastroesophageal junction (GEJ) adenocarcinoma","Biomarker":"PD-L1, HER2-positive","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma"},{"pdf_link":"Study_33.pdf","index":11,"AA_Date":"2025-02-14","Drug_Name":"Romvimza (vimseltinib)","Brand_Name":"Romvimza","Active_Ingredient":"vimseltinib","Approved_Indication":"the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.","Company_name":"Deciphera Pharmaceuticals, LLC","Relevant Expedited Programs":"Priority Review","Approval_Details":["On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.","Full prescribing information for Romvimza will be posted on Drugs@FDA.","Efficacy was evaluated in MOTION (NCT05059262), a double-blind, multicenter, randomized (2:1), placebo-controlled trial in patients with TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. Eligible patients had a confirmed diagnosis of TGCT with measurable disease (RECIST v1.1) with at least one lesion having a minimum size of 2 cm.","Patients were randomized to placebo or vimseltinib, 30 mg twice weekly administered for 24 weeks, during the double-blind period (Part 1). During the open-label period (Part 2), patients could continue vimseltinib and those receiving placebos could crossover to vimseltinib. Randomization was stratified by tumor location (lower limb versus all other) and region (United States versus Non-US). A total of 123 patients were randomized: 83 to the vimseltinib arm and 40 to placebo during Part 1.","The major efficacy outcome measure was overall response rate (ORR) assessed by blinded independent radiological review at week 25. ORR was 40% (95% CI: 29%, 51%) in the vimseltinib arm and 0% (95% CI: 0%, 9%) in the placebo arm (p-value <0.0001). Median duration of response (DOR) was not reached in the vimseltinib arm, and based on an additional 6 months of follow-up, 28 responders (85%) had a DOR \u22656 months and 19 (58%) had a DOR \u22659 months. The primary endpoint was supported by statistically significant improvements in active range of motion, patient-reported physical functioning, and patient-reported pain observed in the vimseltinib arm compared to the placebo arm at week 25.","The most common adverse reactions (\u226520%), including laboratory abnormalities, were increased aspartate aminotransferase, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased alanine aminotransferase.","The recommended vimseltinib dose is 30 mg orally twice weekly, with a minimum of 72 hours between doses.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitateat240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","02\/14\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor"},{"pdf_link":"Study_305.pdf","index":12,"AA_Date":"2025-02-12","Drug_Name":"Adcetris (brentuximab vedotin)","Brand_Name":"Adcetris","Active_Ingredient":"brentuximab vedotin","Approved_Indication":"the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.","Company_name":"Seagen Inc., a subsidiary of Pfizer","Relevant Expedited Programs":"","Approval_Details":["On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.","Full prescribing information for Adcetris will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures included progression-free survival (PFS) and objective response rate (ORR) per 2014 Lugano Criteria. The trial demonstrated a statistically significant OS improvement with a median OS of 13.8 months (95% CI: 10.3, 18.8) in the BV+R2 arm and 8.5 months (95% CI: 5.4, 11.7) in the Pbo+R2 arm (Hazard ratio [HR] 0.63, 95% CI: 0.45, 0.89; p-value 0.0085). The trial also demonstrated a statistically significant improvement in PFS and ORR. Median PFS was 4.2 months (95% CI: 2.9, 7.1) with BV+R2 and 2.6 months (95% CI: 1.4, 3.1) with Pbo+R2 (HR 0.53, 95% CI: 0.38, 0.73; p-value <0.0001). The ORR was 64.3% (95% CI: 54.7, 73.1) and 41.5% (95% CI: 32.5, 51.0), respectively.","The most common adverse reactions (\u226520%), excluding laboratory abnormalities in the BV+R2 arm were fatigue, diarrhea, peripheral neuropathy, rash, pneumonia, and COVID-19 infection. Grade 3 to 4 laboratory abnormalities occurring in more than 10% were decreased neutrophils, decreased lymphocytes, decreased platelets, and decreased hemoglobin. Peripheral neuropathy developed or worsened in 27% of patients, was predominantly sensory, and led to brentuximab vedotin dose reduction in 6% and discontinuation in 4.5%.\u00a0"],"Broad_Tumor":"Large B-cell lymphoma (LBCL)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell"},{"pdf_link":"Study_166.pdf","index":13,"AA_Date":"2025-02-11","Drug_Name":"Gomekli (mirdametinib)","Brand_Name":"Gomekli","Active_Ingredient":"mirdametinib","Approved_Indication":"the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.","Company_name":"SpringWorks Therapeutics, Inc.","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.","Full prescribing information for Gomekli will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was confirmed overall response rate (ORR), defined as the percentage of patients with complete response (disappearance of the target PN) or partial response (\u226520% reduction in PN volume). Responses were assessed by blinded independent central review using volumetric MRI analysis per Response Evaluation in Neurofibromatosis and Schwannomatosis criteria, modified to require confirmation of responses within 2 to 6 months during the 24-cycle treatment phase. Confirmed ORR was 41% for adults (95% CI: 29, 55) and 52% in the pediatric cohort (95% CI: 38, 65).","The most common adverse reactions (>25%) in adult patients were rash, diarrhea, nausea, musculoskeletal pain, vomiting, and fatigue. The most common Grade 3 or 4 laboratory abnormality (>2%) was increased creatine phosphokinase.","The most common adverse reactions (>25%) in pediatric patients were rash, diarrhea, musculoskeletal pain, abdominal pain, vomiting, headache, paronychia, left ventricular dysfunction, and nausea. The most common Grade 3 or 4 laboratory abnormalities (>2%) were decreased neutrophil count and increased creatine phosphokinase.","Mirdametinib can also cause left ventricular dysfunction and ocular toxicity including retinal vein occlusion, retinal pigment epithelial detachment and blurred vision. Mirdametinib should be withheld, dosage reduced or permanently discontinued based on the severity of adverse reactions.","See the prescribing information for the recommended dose based on body surface area.","This review used the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Neurofibromatosis type 1 (NF1), Plexiform neurofibromas (PN)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic"},{"pdf_link":"Study_246.pdf","index":14,"AA_Date":"2025-02-06","Drug_Name":"Grafapex (treosulfan)","Brand_Name":"Grafapex","Active_Ingredient":"treosulfan","Approved_Indication":"the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).","Company_name":"medac GmbH","Relevant Expedited Programs":"","Approval_Details":["On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).","Full prescribing information for Grafapex will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was overall survival (OS), defined as the time from randomization until death from any cause. The hazard ratio for OS (stratified by donor type and risk group) compared to busulfan was 0.67 (95% CI: 0.51, 0.90) in the randomized population, 0.73 (95% CI: 0.51, 1.06) in patients with AML, and 0.64 (95% CI: 0.40, 1.02) in patients with MDS.","The most common adverse reactions (\u226520%) were musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Selected Grade 3 or 4 nonhematological laboratory abnormalities were increased GGT, increased bilirubin, increased ALT, increased AST, and increased creatinine.","The recommended treosulfan dose is 10 g\/m2 daily on days -4, -3, and -2 in combination with fludarabine 30 mg\/m2 daily on days -6, -5, -4, -3, and -2, and allogeneic hematopoietic stem cell infusion on day 0."],"Broad_Tumor":"Acute myeloid leukemia (AML)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or"},{"pdf_link":"Study_5.pdf","index":15,"AA_Date":"2025-01-27","Drug_Name":"Enhertu (fam-trastuzumab deruxtecan-nxki)","Brand_Name":"Enhertu","Active_Ingredient":"fam-trastuzumab deruxtecan-nxki","Approved_Indication":"the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+\/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.","Company_name":"Daiichi Sankyo, Inc.","Relevant Expedited Programs":"Priority Review","Approval_Details":["On January 27, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+\/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.","FDA also approved the Ventana\u2019s PATHWAY anti-HER-2 (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic device to identify patients with HER2-ultralow (IHC 0 with membrane staining) breast cancer for treatment with Enhertu. This assay was previously approved to identify patients with HER2-low (IHC 1+ or IHC 2+\/ISH-) breast cancer for treatment with Enhertu.  ","Full prescribing information for Enhertu will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) in patients with HER2-low breast cancer assessed by blinded independent central review (BICR) based on RECIST v1.1. Additional efficacy outcome measures were PFS assessed by BICR based on RECIST v1.1 in the overall population, overall survival (OS) in patients with HER2-low breast cancer, and OS in the overall population. The trial demonstrated a statistically significant improvement in PFS in patients with HER2-low breast cancer (n=713). Median PFS was 13.2 months in the fam-trastuzumab deruxtecan-nxki arm and 8.1 months in the chemotherapy arm (Hazard ratio [HR] 0.62 [95% CI: 0.52, 0.75]; p-value <0.0001). The trial also demonstrated a statistically significant improvement in PFS in the overall population. Median PFS was 13.2 and 8.1 months in the fam-trastuzumab deruxtecan-nxki and chemotherapy arms, respectively (HR 0.64 [95% CI: 0.54, 0.76]; p-value <0.0001). At the time of the PFS final analysis, OS data was immature, and a total of 335 (39%) patients had died across both trial arms in the overall population. \u00a0","In exploratory analyses in the HER2-ultralow subgroup (n=153 patients), median PFS was 15.1 months in the fam-trastuzumab deruxtecan-nxki arm and 8.3 months in the chemotherapy arm with a HR of 0.76 (95% CI: 0.49, 1.17). In patients with measurable disease at baseline, confirmed objective response rate (ORR) assessed by BICR was 65.7% and 30.8% in the fam-trastuzumab deruxtecan-nxki and chemotherapy arms, respectively. \u00a0","The most common adverse reactions (\u226520%), including laboratory abnormalities, were decreased white blood cell count, decreased neutrophil count, nausea, decreased hemoglobin, decreased lymphocyte count, fatigue, decreased platelet count, alopecia, increased alanine aminotransferase, increased blood alkaline phosphatase, increased aspartate aminotransferase, decreased blood potassium, diarrhea, vomiting, constipation, decreased appetite, COVID-19 infection, and musculoskeletal pain.","The recommended fam-trastuzumab deruxtecan-nxki dosage is 5.4 mg\/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.","This review used the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Breast cancer","Biomarker":"Hormone Receptor, Hormone receptor (HR)-positive, HER2-low","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2"},{"pdf_link":"Study_25.pdf","index":16,"AA_Date":"2025-01-24","Drug_Name":"","Brand_Name":"","Active_Ingredient":"","Approved_Indication":"he U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and discuss testing options for DPD deficiency with their patients. ","Company_name":"","Relevant Expedited Programs":"","Approval_Details":["The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and discuss testing options for DPD deficiency with their patients. ","Fluoropyrimidines are a class of anti-cancer drugs that include fluorouracil (5-FU) and capecitabine, a prodrug of 5-FU. The DPYD gene encodes the enzyme DPD, which breaks down >80% of fluorouracil. Patients with certain homozygous or compound heterozygous variants in the DPYD gene, known to result in complete or near complete absence of DPD activity (complete DPD deficiency), are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious, including fatal, adverse reactions."],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine"},{"pdf_link":"Study_203.pdf","index":17,"AA_Date":"2025-01-17","Drug_Name":"Datroway (datopotamab deruxtecan-dlnk)","Brand_Name":"Datroway","Active_Ingredient":"datopotamab deruxtecan-dlnk","Approved_Indication":"the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+\/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.","Company_name":"Daiichi Sankyo, Inc.","Relevant Expedited Programs":"","Approval_Details":["On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+\/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.","Full prescribing information for Datroway will be posted on Drugs@FDA.","Efficacy was evaluated in TROPION-Breast01 (NCT05104866), a multicenter, open-label, randomized trial. Patients must have experienced disease progression, been deemed unsuitable for further endocrine therapy, and have received one or two lines of prior chemotherapy for unresectable or metastatic disease. Patients were excluded for a history of ILD\/pneumonitis requiring steroids, ongoing ILD\/pneumonitis, clinically active brain metastases, or clinically significant corneal disease. Patients also were excluded for ECOG performance status >1.","Randomization was stratified by previous lines of chemotherapy, prior CDK4\/6 inhibitor treatment, and geographical region. A total of 732 patients were randomized (1:1) to datopotamab deruxtecan-dlnk (n=365) or investigator\u2019s choice of chemotherapy (n=367); eribulin (60%), capecitabine (21%), vinorelbine (10%), or gemcitabine (9%).","The major efficacy outcome measures were progression-free survival (PFS), assessed by blinded independent central review (BICR), based on RECIST v1.1 and overall survival (OS). Additional efficacy outcomes included confirmed objective response rate (ORR) and duration of response (DOR) by BICR. Median PFS was 6.9 months (95% CI: 5.7, 7.4) in the datopotamab deruxtecan-dlnk arm and 4.9 months (95% CI: 4.2, 5.5) in the chemotherapy arm (Hazard ratio 0.63 [95% CI: 0.52, 0.76] two-sided p-value <0.0001). Median OS was 18.6 months (95% CI: 17.3, 20.1) in the datopotamab deruxtecan-dlnk arm and 18.3 months (95% CI: 17.3, 20.5) in the chemotherapy arm (Hazard ratio 1.01 [95% CI: 0.83, 1.22]; two-sided p-value was not statistically significant). Confirmed ORR was 36% (95% CI: 31, 42) and 23% (95% CI: 19, 28) and median DOR was 6.7 months (95% CI: 5.6, 9.8) and 5.7 months (95% CI: 4.9, 6.8) in the datopotamab deruxtecan-dlnk and chemotherapy arms, respectively.","The most common adverse reactions (\u226520%), including laboratory abnormalities, were stomatitis, nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, increased ALT, keratitis, increased AST, and increased alkaline phosphatase.","The recommended datopotamab deruxtecan-dlnk dose is 6 mg\/kg (maximum of 540 mg for patients \u226590 kg), administered as an intravenous infusion, once every 3 weeks (21-day cycle), until disease progression or unacceptable toxicity.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitateat240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","01\/17\/2025\n"],"Efficacy and Safety":null,"Broad_Tumor":"Breast cancer","Biomarker":"Hormone Receptor, Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2, human epidermal growth factor receptor 2 (HER2)-negative","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast"},{"pdf_link":"Study_11.pdf","index":19,"AA_Date":"2025-01-16","Drug_Name":"Calquence (acalabrutinib)","Brand_Name":"Calquence","Active_Ingredient":"acalabrutinib","Approved_Indication":"the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).","Company_name":"AstraZeneca","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).","FDA also granted traditional approval to acalabrutinib as a single agent for adults with previously treated MCL. Acalabrutinib received accelerated approval for this indication in 2017.","Full prescribing information for Calquence will be posted on Drugs@FDA."],"Efficacy and Safety":["Efficacy was based on progression-free survival (PFS), as assessed by an independent review committee. With a median follow-up of 49.8 months, PFS was statistically significantly longer in the acalabrutinib arm (hazard ratio 0.73 [95% CI: 0.57, 0.94], p-value 0.016). The median PFS was 66.4 months (95% CI: 55.1, not estimable) in the acalabrutinib plus BR arm and 49.6 months (95% CI: 36.0, 64.1) in the placebo plus BR arm.","Serious adverse reactions occurred in 69% of patients with acalabrutinib plus BR, and fatal adverse reactions occurred in 12%. Serious adverse reactions reported in \u22652% of patients were pneumonia, COVID-19, pyrexia, second primary malignancy, rash, febrile neutropenia, atrial fibrillation, sepsis, and anemia.","The recommended acalabrutinib dose is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland\u2019s Swissmedic. The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics."],"Broad_Tumor":"Mantle cell lymphoma (MCL)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma"},{"pdf_link":"Study_28.pdf","index":18,"AA_Date":"2025-01-16","Drug_Name":"Lumakras (sotorasib)","Brand_Name":"Lumakras","Active_Ingredient":"sotorasib","Approved_Indication":"the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.","Company_name":"Amgen Inc.","Relevant Expedited Programs":"Orphan Drug Designation","Approval_Details":["On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.","Today, the FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to aid in identifying patients with colorectal cancer whose tumors harbor KRAS G12C mutations and who may be eligible for Lumakras with Vectibix.","Full prescribing information for Lumakras and Vectibix will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) as evaluated by blinded independent central review according to RECIST v1.1. Additional efficacy outcome measures included overall survival (OS), overall response rate (ORR), and duration of response (DOR). The study was not statistically powered for OS. Median PFS was 5.6 months (95% CI: 4.2, 6.3) in the sotorasib 960 mg\/panitumumab arm and 2 months (95% CI: 1.9, 3.9) in the SOC arm (hazard ratio 0.48 [95% CI: 0.3, 0.78] 2-sided p-value 0.005). The final analysis of OS was not statistically significant. ORR was 26% (95% CI: 15, 40) in the sotorasib 960 mg\/panitumumab arm and 0 (95% CI: 0, 7) in the SOC arm. Median DOR was 4.4 months (range: 1.9+, 6+) in the sotorasib 960 mg\/panitumumab arm.","The final analysis of PFS for patients randomized to the sotorasib 240 mg\/panitumumab arm compared to the SOC arm was not statistically significant.","The most common adverse reactions (\u226520%) for sotorasib 960 mg\/panitumumab were rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain. The most common Grade 3-4 laboratory abnormalities in \u2265 2 patients were decreased magnesium, decreased potassium, decreased corrected calcium, and increased potassium.","The recommended sotorasib dose is 960 mg orally once daily. The recommended panitumumab dose is 6 mg\/kg administered as an IV infusion every 14 days until disease progression, unacceptable toxicity, or until sotorasib is withheld or discontinued. Administer the first dose of sotorasib before the first panitumumab infusion.","This review used the\u00a0Real-Time Oncology Review\u00a0(RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and\u00a0the\u00a0Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted orphan drug designation. FDA expedited programs are described in the\u00a0Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics."],"Broad_Tumor":"Colorectal cancer (CRC)","Biomarker":"KRAS G12C","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer"},{"pdf_link":"Study_72.pdf","index":20,"AA_Date":"2024-12-27","Drug_Name":"Opdivo (nivolumab)","Brand_Name":"Opdivo","Active_Ingredient":"nivolumab","Approved_Indication":"the Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb Company) for subcutaneous injection across approved adult, solid tumor nivolumab (Opdivo, Bristol Myers Squibb Company) indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.","Company_name":"Bristol Myers Squibb Company","Relevant Expedited Programs":"","Approval_Details":["On December 27, 2024, the Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb Company) for subcutaneous injection across approved adult, solid tumor nivolumab (Opdivo, Bristol Myers Squibb Company) indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.","The approval includes indications for renal cell carcinoma, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal carcinoma, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Opdivo Qvantig is not indicated in combination with intravenous ipilimumab. The prescribing information provides specific indications and further information for Opdivo Qvantig at Drugs@FDA."],"Efficacy and Safety":["The primary objective was to assess the nivolumab exposure of subcutaneous administration of OPDIVO QVANTIG compared to intravenous nivolumab. The key secondary objective was to evaluate overall response rate (ORR), assessed by blinded independent central review. The trial met the predefined acceptance margin for pharmacokinetic endpoints, with the lower boundary of 90% confidence interval of geometric mean ratios of not less than 0.8 for both serum nivolumab Cavg over 28 days and Cmin at steady state. ORR was 24% (95% CI: 19,30) in the subcutaneous nivolumab and hyaluronidase-nvhy arm and 18% (95% CI: 14, 24) in the intravenous nivolumab arm.","In general, CHECKMATE-67T showed a similar safety profile between OPDIVO QVANTIG and intravenous nivolumab. The most common adverse reactions (\u226510%) were fatigue, musculoskeletal pain, pruritus, rash, and cough.","The recommended dosage depends on the specific indication and is either 600 mg nivolumab and 10,000 units hyaluronidase every 2 weeks; 900 mg nivolumab and 15,000 units of hyaluronidase every 3 weeks; or 1,200 mg nivolumab and 20,000 units hyaluronidase every 4 weeks until disease progression, unacceptable toxicity, or as indicated in the prescribing information."],"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection"},{"pdf_link":"Study_274.pdf","index":3,"AA_Date":"2024-12-20","Drug_Name":"Braftovi (encorafenib)","Brand_Name":"Braftovi","Active_Ingredient":"encorafenib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.","Company_name":"Array BioPharma Inc., a subsidiary of Pfizer Inc.","Relevant Expedited Programs":"Accelerated Approval;Priority Review","Approval_Details":["On December 20, 2024, the Food and Drug Administration granted accelerated approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.","Full prescribing information for Braftovi will be posted on Drugs@FDA.  "],"Efficacy and Safety":["The trial was subsequently amended to limit randomization (1:1) to the encorafenib +cetuximab+mFOLFOX6 arm and the control arm. Treatment in all arms continued until disease progression, unacceptable toxicity, consent withdrawal, lost to follow-up, or death. The results of the encorafenib + cetuximab + mFOLFOX6 arm compared to the control arm served as the basis of this accelerated approval and are described below.","The major efficacy outcome measure was confirmed objective response rate (ORR) assessed by blinded independent central review and evaluated in the first 110 patients randomized in each arm. ORR was 61% (95% CI: 52%, 70%) in the encorafenib+ cetuximab, + mFOLFOX6 arm and 40% (95% CI: 31%, 49%) in the control arm. Median DoR was 13.9 months (95% CI: 8.5, not estimable) and 11.1 months (95% CI: 6.7, 12.7) in the respective arms.","Evaluation of progression-free survival and overall survival in the ongoing BREAKWATER trial will serve as post-marketing confirmatory evidence for this accelerated approval. This application is an example of the Oncology Center of Excellence\u2019s Project FrontRunner aimed at moving important therapies to earlier disease settings.","The most common adverse reactions (\u226525%) were peripheral neuropathy, nausea, fatigue, rash, diarrhea, decreased appetite, vomiting, hemorrhage, abdominal pain, and pyrexia. The most common Grade 3 or 4 laboratory abnormalities (\u226520%) were increased lipase and decreased neutrophil count.","The recommended encorafenib dose is 300 mg (four 75 mg capsules) orally once daily in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity. Full dosing information is provided in the prescribing information.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada. The application review is ongoing at the other regulatory agencies.","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Colorectal cancer (CRC)","Biomarker":"BRAF V600, BRAF V600E","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf"},{"pdf_link":"Study_82.pdf","index":23,"AA_Date":"2024-12-18","Drug_Name":"Ensacove (ensartinib)","Brand_Name":"Ensacove","Active_Ingredient":"ensartinib","Approved_Indication":"the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.","Company_name":"Xcovery Holdings, Inc.","Relevant Expedited Programs":"","Approval_Details":["On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.","Full prescribing information for Ensacove will be posted on Drugs@FDA."],"Efficacy and Safety":["The main efficacy outcome measure was progression-free survival (PFS) as evaluated by blinded independent central review. The key secondary efficacy outcome measure was overall survival (OS). Ensartinib demonstrated a statistically significant PFS improvement compared to crizotinib with a hazard ratio (HR) of 0.56 (95% CI: 0.40, 0.79; p-value 0.0007). The median PFS was 25.8 months (95% CI: 21.8, not estimable) in the ensartinib arm and 12.7 months (95% CI: 9.2, 16.6) in the crizotinib arm. There was no statistically significant difference in OS (HR 0.88 [95% CI: 0.63, 1.23], p-value 0.4570).","The most common adverse reactions (\u226520%) were rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.","The recommended ensartinib dose is 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer"},{"pdf_link":"Study_105.pdf","index":22,"AA_Date":"2024-12-18","Drug_Name":"Ryoncil (remestemcel-L-rknd)","Brand_Name":"Ryoncil","Active_Ingredient":"remestemcel-L-rknd","Approved_Indication":"the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy.","Company_name":"Mesoblast, Inc.","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy.","Full prescribing information for Ryoncil will be posted here"],"Efficacy and Safety":["The main efficacy outcome measures were overall response rate (ORR) at Day 28 and duration of overall response. The ORR included complete and partial response rates (CR and PR). ORR at Day 28 was 70% (95% confidence interval, CI: 56.4, 82.0), including a CR rate of 30% (95% CI: 18.0, 43.6) and a PR rate of 41% (95% CI: 27.6, 55.0). The median duration of response calculated from response at Day 28 to either progression, new systemic therapy for aGVHD, or any cause death, was 54 days (range 7, 159+).","The most common nonlaboratory adverse reactions (incidence \u226520%) were viral infectious disorders, bacterial infectious disorders, infection \u2013 pathogen unspecified, pyrexia, hemorrhage, edema, abdominal pain and hypertension.","The recommended dose is 2 X 106 MSC\/kg body weight per intravenous infusion given twice a week for 4 consecutive weeks for a total of 8 infusions. Infusions are administered at least 3 days apart. Treatment may be continued based on response at 28 days after initial remestemcel-L-rknd.","Remestemcel-L-rknd has fast track, orphan drug and priority review designations. FDA expedited programs are described in the\u00a0Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. A description of FDA expedited programs for regenerative medicine advanced therapies is in the\u00a0Guidance for Industry:\u00a0Expedited Programs for Regenerative Medicine Therapies for Serious Conditions."],"Broad_Tumor":"Graft versus host disease (GVHD)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric"},{"pdf_link":"Study_179.pdf","index":24,"AA_Date":"2024-12-13","Drug_Name":"Unloxcyt (cosibelimab-ipdl)","Brand_Name":"Unloxcyt","Active_Ingredient":"cosibelimab-ipdl","Approved_Indication":"the Food and Drug Administration approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.","Company_name":"Checkpoint Therapeutics, Inc.","Relevant Expedited Programs":"","Approval_Details":["On December 13, 2024, the Food and Drug Administration approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.","Full prescribing information for Unloxcyt will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as assessed by an independent central review committee (IRC) according to RECIST version 1.1. For patients with laCSCC with externally visible target lesions not assessable by radiologic imaging, ORR was determined by ICR assessments of digital photography (WHO criteria). ORR was 47% (95% CI: 36, 59) for patients with mCSCC (n=78) and 48% (95% CI: 30, 67) for patients with laCSCC (n=31). Median DOR was not reached (range: 1.4+, 34.1+) in patients with mCSCC and 17.7 months (range: 3.7+, 17.7) in patients with laCSCC.","The most common adverse reactions (\u226510%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritis, edema, localized infection, and urinary tract infection."],"Broad_Tumor":"Cutaneous squamous cell carcinoma (cSCC)","Biomarker":"PD-L1","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma"},{"pdf_link":"Study_17.pdf","index":4,"AA_Date":"2024-12-04","Drug_Name":"Bizengri (zenocutuzumab-zbco)","Brand_Name":"Bizengri","Active_Ingredient":"zenocutuzumab-zbco","Approved_Indication":"the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with the following:","Company_name":"Merus N.V.","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with the following:","This represents the first FDA approval of a systemic therapy for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.","Full prescribing information for Bizengri will be posted on Drugs@FDA.","Efficacy was evaluated in the eNRGy study (NCT02912949), a multicenter, open-label, multicohort trial. The trial enrolled 64 adults with advanced or metastatic NRG1 fusion-positive NSCLC and 30 adults with advanced or metastatic NRG1 fusion-positive pancreatic adenocarcinoma who had disease progression following standard of care treatment. Identification of positive NRG1 gene fusion status was prospectively determined by next generation sequencing assays.","The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR), determined by blinded independent central review according to RECIST v1.1. For NSCLC, ORR was 33% (95% CI: 22%, 46%) and median DOR was 7.4 months (95% CI: 4.0, 16.6). For pancreatic adenocarcinoma, ORR was 40% (95% CI: 23%, 59%) and the DOR range was 3.7 months to 16.6 months.","In the pooled safety population, the most common adverse reactions (\u226510%) were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities (\u226510%) were increased gamma-glutamyl transferase, decreased hemoglobin, decreased sodium, and decreased platelets. The prescribing information includes a Boxed Warning for embryo-fetal toxicity.","The recommended zenocutuzumab-zbco dose is 750 mg, as an intravenous infusion every 2 weeks, until disease progression or unacceptable toxicity."],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic"},{"pdf_link":"Study_263.pdf","index":25,"AA_Date":"2024-12-04","Drug_Name":"Imfinzi (durvalumab)","Brand_Name":"Imfinzi","Active_Ingredient":"durvalumab","Approved_Indication":"the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.","Company_name":"AstraZeneca","Relevant Expedited Programs":"Priority Review","Approval_Details":["On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.","Full prescribing information for Imfinzi will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) assessed by blinded independent central review for the comparison between durvalumab as a single agent and placebo. Durvalumab demonstrated a statistically significant OS improvement compared to placebo with a hazard ratio (HR) of 0.73 (95% CI: 0.57, 0.93; p-value 0.0104). The median OS was 55.9 months (95% CI: 37.3, not reached) in the durvalumab arm and 33.4 months (95% CI: 25.5, 39.9) in the placebo arm. Durvalumab also demonstrated a statistically significant PFS improvement compared to placebo with HR of 0.76 (95% CI: 0.61, 0.95; p-value 0.0161). The median PFS was 16.6 months (95% CI: 10.2, 28.2) and 9.2 months (95% CI: 7.4, 12.9) in the durvalumab and placebo arms, respectively.","The most common adverse reactions (\u226520%) were pneumonitis or radiation pneumonitis and fatigue.","The recommended durvalumab dose is 1,500 mg every 4 weeks for patients with a body weight of \u226530 kg and 20 mg\/kg every 4 weeks for patients with a body weight of <30 kg until disease progression or unacceptable toxicity or a maximum of 24 months.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, and Switzerland\u2019s Swissmedic (SMC). The European Medicines Agency (EMA) was an official observer of this review. The application reviews may be ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer"},{"pdf_link":"Study_188.pdf","index":6,"AA_Date":"2024-11-20","Drug_Name":"Ziihera (zanidatamab-hrii)","Brand_Name":"Ziihera","Active_Ingredient":"zanidatamab-hrii","Approved_Indication":"the Food and Drug Administration granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.","Company_name":"Jazz Pharmaceuticals, Inc.","Relevant Expedited Programs":"Accelerated Approval;Breakthrough Therapy Designation;Orphan Drug Designation;Priority Review","Approval_Details":["On November 20, 2024, the Food and Drug Administration granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.","Today, the FDA also approved VENTANA PATHWAY anti-HER-2\/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.\/Roche Diagnostics) as a companion diagnostic device to aid in identifying patients with BTC who may be eligible for treatment with Ziihera.","Full prescribing information for Ziihera will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as determined by an independent central review according to RECIST v1.1. ORR was 52% (95% CI: 39, 65) and median DOR was 14.9 months (95% CI: 7.4, not estimable).","The prescribing information contains a boxed warning for embryo-fetal toxicity. The most common adverse reactions reported in at least 20% of patients who received zanidatamab-hrii were diarrhea, infusion-related reactions, abdominal pain, and fatigue.","The recommended zanidatamab-hrii dose is 20 mg\/kg administered as an intravenous infusion once every 2 weeks until progression or unacceptable toxicity. \u00a0","This review used\u00a0the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review, breakthrough therapy designation, and orphan drug designation. FDA expedited programs are described in the\u00a0Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics."],"Broad_Tumor":"Biliary tract cancer (BTC)","Biomarker":"HER2-positive","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2"},{"pdf_link":"Study_43.pdf","index":28,"AA_Date":"2024-11-19","Drug_Name":"Fludarabine Phosphate Injection (updated drug labeling for fludarabine phosphate)","Brand_Name":"Fludarabine Phosphate Injection","Active_Ingredient":"updated drug labeling for fludarabine phosphate","Approved_Indication":"the Food and Drug Administration approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection, Sandoz) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the third drug to receive a labeling update under Project Renewal.","Company_name":"Phosphate Injection, Sandoz","Relevant Expedited Programs":"","Approval_Details":["On November 19, 2024, the Food and Drug Administration approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection, Sandoz) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the third drug to receive a labeling update under Project Renewal.","Full prescribing information for fludarabine phosphate injection will be posted on Drugs@FDA.","Project Renewal is a collaborative program that leverages external oncology experts and early-career scientists to review existing published literature and gain first-hand experience in the evaluation of evidence for independent FDA review. Project Renewal is intended to keep older, commonly prescribed oncology drugs\u2019 labeling up to date, while providing transparency on FDA\u2019s evaluation process and evidentiary standards and improving awareness of drug labeling as an information resource.","Fludarabine Phosphate Injection is now approved for the following new and revised indications:","Additional labeling revisions include:","Project Renewal is limited to updating labeling of older oncology drugs with decades of use and substantial post-marketing experience. For information on the key studies supporting a new or revised indication, see the prescribing information for Fludarabine Phosphate Injection.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","11\/20\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-updated-drug-labeling-fludarabine-phosphate-under-project-renewal"},{"pdf_link":"Study_77.pdf","index":29,"AA_Date":"2024-11-15","Drug_Name":"Revuforj (revumenib)","Brand_Name":"Revuforj","Active_Ingredient":"revumenib","Approved_Indication":"the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.","Company_name":"Syndax Pharmaceuticals, Inc.","Relevant Expedited Programs":"Orphan Drug Designation;Priority Review","Approval_Details":["On November 15, 2024, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.","Full prescribing information for Revuforj will be posted on Drugs@FDA."],"Efficacy and Safety":["The main efficacy outcome measures were complete remission (CR) plus CR with partial hematologic recovery (CRh), the duration of CR+CRh, and conversion from transfusion dependence to independence. The CR+CRh rate was 21.2% (95% CI: 13.8, 30.3), and the median CR+CRh duration was 6.4 months (95% CI: 2.7, not estimable). Of the 22 patients achieving CR or CRh, the median time to CR or CRh was 1.9 months (range: 0.9, 5.6 months). Among the 83 patients dependent on red blood cell (RBC) and\/or platelet transfusions at baseline, 12 (14%) became independent of RBC and platelet transfusions during any 56-day post-baseline period. Of the 21 patients independent of both RBC and platelet transfusions at baseline, 10 (48%) remained transfusion independent during any 56-day post-baseline period.","The most common adverse reactions (\u226520%) were hemorrhage, nausea, increased phosphate, musculoskeletal pain, infection, increased aspartate aminotransferase, febrile neutropenia, increased alanine aminotransferase, increased intact parathyroid hormone, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, decreased phosphate, increased triglycerides, decreased potassium, decreased appetite, constipation, edema, viral infection, fatigue, and increased alkaline phosphatase.","The recommended revumenib dose varies by patient weight and concomitant use of strong CYP3A4 inhibitors. See the prescribing information for specific dosage information. Due to an anticipated delay in commercial availability of the lowest dose strength of revumenib, which may be used to treat patients who weigh < 40 kg, revumenib will be available through an expanded access program to allow for dosing of patients who weigh < 40 kg (information available here: NCT05918913).","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. The FDA approved this application 6 weeks ahead of the FDA goal date.","This application was granted priority review. Revumenib has breakthrough designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics."],"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation"},{"pdf_link":"Study_194.pdf","index":30,"AA_Date":"2024-11-08","Drug_Name":"Aucatzyl (obecabtagene autoleucel)","Brand_Name":"Aucatzyl","Active_Ingredient":"obecabtagene autoleucel","Approved_Indication":"the Food and Drug Administration approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","Company_name":"Autolus Inc.","Relevant Expedited Programs":"","Approval_Details":["On November 8, 2024, the Food and Drug Administration approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","Full prescribing information for Aucatzyl will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measures were rate and duration of complete remission (CR) achieved within 3 months after infusion. Additional outcome measures were rate and duration of overall complete remission which includes complete remission and complete remission with incomplete hematologic recovery (CRi), at any time. Of the 65 patients evaluable for efficacy, 27 patients (42%; 95% confidence interval [CI]: 29%, 54%) achieved CR within 3 months. The median duration of CR achieved within 3 months was 14.1 months (95% CI: 6.1, not reached).\u00a0","The prescribing information has a boxed warning for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and T cell malignancies. CRS occurred in 75% (Grade 3, 3%) and neurologic toxicities occurred in 64% (Grade \u22653, 12%), including ICANS in 24% (Grade \u22653, 7%).The most common non-laboratory adverse reactions (incidence \u2265 20%) included CRS, infections-pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, ICANS, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.","The total recommended dose of obecabtagene autoleucel is 410 X 106 CD19 chimeric antigen receptor (CAR)-positive viable T cells to be administered as split dose infusion on Day 1 and Day 10 (\u00b12 days) based on bone marrow blast assessment and preceded by fludarabine and cyclophosphamide lymphodepleting chemotherapy.\u00a0","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.\u00a0"],"Broad_Tumor":"B-cell precursor acute lymphoblastic leukemia (BCP ALL)","Biomarker":"CD19","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute"},{"pdf_link":"Study_233.pdf","index":7,"AA_Date":"2024-10-29","Drug_Name":"Scemblix (asciminib)","Brand_Name":"Scemblix","Active_Ingredient":"asciminib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).","Company_name":"Novartis AG","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).","Full prescribing information for Scemblix will be posted on Drugs@FDA. "],"Efficacy and Safety":["In the pooled safety population in patients with newly diagnosed and previously treated Ph+ CML in CP, the most common adverse reactions (\u226520%) were musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea. The most common laboratory abnormalities (\u226540%) in patients with newly diagnosed Ph+ CML in CP were decreased lymphocyte count, decreased leukocyte count, decreased platelet count, decreased neutrophil count, and decreased calcium corrected.","The recommended asciminib dosage is 80 mg taken orally once daily at approximately the same time of day or 40 mg taken orally twice daily at approximately 12-hour intervals.","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada (HC) and Switzerland\u2019s Swissmedic (SMC). The application reviews are ongoing at the other regulatory agencies.","This review used the\u00a0Real-Time Oncology Review\u00a0(RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and\u00a0the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. The FDA approved this application one month ahead of the FDA goal date."],"Broad_Tumor":"Chronic myeloid leukemia (CML)","Biomarker":"Philadelphia chromosome-positive, Philadelphia Chromosome, Ph+","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia"},{"pdf_link":"Study_253.pdf","index":32,"AA_Date":"2024-10-18","Drug_Name":"Vyloy (zolbetuximab-clzb)","Brand_Name":"Vyloy","Active_Ingredient":"zolbetuximab-clzb","Approved_Indication":"the Food and Drug Administration approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.","Company_name":"Astellas Pharma US, Inc.","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On October 18, 2024, the Food and Drug Administration approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.","Today, FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay (Ventana Medical Systems, Inc.\/Roche Diagnostics) as a companion diagnostic device to identify patients with gastric or GEJ adenocarcinoma who may be eligible for treatment with zolbetuximab.","Full prescribing information for Vyloy will be posted on Drugs@FDA."],"Efficacy and Safety":["In SPOTLIGHT, 565 patients were randomized to receive zolbetuximab-clzb with mFOLFOX6 chemotherapy or placebo with mFOLFOX6 chemotherapy. Median PFS was 10.6 months (95% CI: 8.9, 12.5) in the zolbetuximab-clzb\/chemotherapy arm and 8.7 months (95% CI: 8.2, 10.3) in the placebo\/chemotherapy arm (hazard ratio [HR] 0.751 [95% CI: 0.598, 0.942]; 1-sided p-value=0.0066). Median OS was 18.2 months (95% CI: 16.4, 22.9) and 15.5 months (95% CI: 13.5, 16.5), respectively, (HR 0.750 [95% CI: 0.601, 0.936]; 1-sided p-value=0.0053).","In GLOW, 507 patients were randomized to receive either zolbetuximab-clzb with CAPOX chemotherapy or placebo with CAPOX chemotherapy. Median PFS was 8.2 months (95% CI: 7.5, 8.8) in the zolbetuximab-clzb\/chemotherapy arm and 6.8 months (95% CI: 6.1, 8.1) in the placebo\/chemotherapy arm (hazard ratio [HR] 0.687 [95% CI: 0.544, 0.866]; 1-sided p-value=0.0007). Median OS was 14.4 months (95% CI: 12.3, 16.5) and 12.2 months (95% CI: 10.3, 13.7), respectively (HR 0.771 [95% CI: 0.615, 0.965]; 1-sided p-value=0.0118).","The most common serious adverse reactions in SPOTLIGHT (\u22652%) were vomiting, nausea, neutropenia, febrile neutropenia, diarrhea, intestinal obstruction, pyrexia, pneumonia, respiratory failure, pulmonary embolism, decreased appetite, and sepsis. The most common serious adverse reactions in GLOW (\u22652%) were vomiting, nausea, decreased appetite, decreased platelet count, upper gastrointestinal hemorrhage, diarrhea, pneumonia, pulmonary embolism, and pyrexia.","The recommended zolbetuximab-clzb dosage with fluoropyrimidine- and platinum-containing chemotherapy is:","This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Gastric or gastroesophageal junction (GEJ) adenocarcinoma","Biomarker":"human epidermal growth factor receptor 2 (HER2)-negative, Human epidermal growth factor receptor 2","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma"},{"pdf_link":"Study_107.pdf","index":33,"AA_Date":"2024-10-10","Drug_Name":"Itovebi (inavolisib)","Brand_Name":"Itovebi","Active_Ingredient":"inavolisib","Approved_Indication":"the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","Company_name":"Genentech, Inc.","Relevant Expedited Programs":"Priority Review","Approval_Details":["On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with inavolisib with palbociclib and fulvestrant.","Full prescribing information for Itovebi will be posted on Drugs@FDA. "],"Efficacy and Safety":["Patients were randomized 1:1 to either inavolisib 9 mg or placebo orally once daily, with palbociclib 125 mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a cycle of 28 days, and fulvestrant 500 mg administered intramuscularly on Cycle 1, Days 1 and 15, and then on Day 1 of every 28-day cycle. Patients received treatment until disease progression or unacceptable toxicity. Randomization was stratified by presence of visceral disease (yes or no), endocrine resistance (primary or secondary), and geographic region (North America\/Western Europe, Asia, other).","The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST version 1.1. Additional efficacy outcome measures included overall survival (OS), investigator-assessed objective response rate (ORR), and duration of response (DOR). Median PFS was 15.0 months (95% CI: 11.3, 20.5) in the inavolisib + palbociclib + fulvestrant arm and 7.3 months (95% CI: 5.6, 9.3) in the placebo + palbociclib + fulvestrant arm (Hazard ratio 0.43 [95% CI: 0.32, 0.59] p-value <0.0001). ORR was 58% (95% CI: 50, 66) in the inavolisib + palbociclib + fulvestrant arm and 25% (95% CI: 19, 32) in the placebo + palbociclib + fulvestrant arm. Median DOR was 18.4 months (95% CI: 10.4, 22.2) and 9.6 months (95% CI: 7.4, 16.6), respectively. Interim analysis of overall survival based on 63% information fraction did not reach statistical significance but was supportive of the overall benefit risk assessment with a HR of 0.64 (95% CI: 0.43, 0.97).","The most common adverse reactions (\u226520%), including laboratory abnormalities, were decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache.","The recommended inavolisib dose is 9 mg taken orally once daily, with or without food, until disease progression or unacceptable toxicity. Refer to the prescribing information for palbociclib and fulvestrant dosing information.","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland\u2019s Swissmedic. The application reviews are ongoing at the other regulatory agencies.","This review used\u00a0the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. The FDA approved this application 7 weeks ahead of the FDA goal date."],"Broad_Tumor":"Breast cancer","Biomarker":"Hormone Receptor, Hormone receptor (HR)-positive, PIK3CA","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive"},{"pdf_link":"Study_7.pdf","index":34,"AA_Date":"2024-10-03","Drug_Name":"Opdivo (nivolumab)","Brand_Name":"Opdivo","Active_Ingredient":"nivolumab","Approved_Indication":"the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors \u2265 4 cm and\/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ","Company_name":"Bristol Myers Squibb Company","Relevant Expedited Programs":"","Approval_Details":["On October 3, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors \u2265 4 cm and\/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ","Full prescribing information for Opdivo will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measure was event-free survival (EFS) by blinded independent central review. Median EFS was not reached (95% CI: 28.9, not estimable [NE]) in the nivolumab arm and 18.4 months (95% CI: 13.6, 28.1) in the chemotherapy arm (hazard ratio 0.58 [95% CI: 0.43, 0.78]; p-value 0.00025). At the prespecified interim analysis, overall survival (OS) was not formally tested for statistical significance; however, a descriptive analysis revealed no detriment.\u00a0","Adverse reactions were similar to those occurring in other clinical trials of nivolumab with chemotherapy. Of those who received neoadjuvant nivolumab, 5.3% were unable to undergo surgery due to adverse reactions compared with 3.5% in the placebo arm. In addition, 4.5% who received neoadjuvant treatment and surgery in the nivolumab arm had delays in surgery due to adverse reactions compared with 3.9% in the placebo arm. See the prescribing information for additional safety information.","The recommended nivolumab dosage is 360 mg every 3 weeks (neoadjuvant treatment) and 480 mg every 4 weeks (adjuvant treatment). Nivolumab should be administered prior to chemotherapy when administered on the same day.\u00a0","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, and Israel\u2019s Ministry of Health (IMoH). The application reviews are ongoing at the other regulatory agencies.\u00a0","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"Epidermal growth factor receptor (EGFR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer"},{"pdf_link":"Study_228.pdf","index":35,"AA_Date":"2024-09-27","Drug_Name":"Retevmo (selpercatinib)","Brand_Name":"Retevmo","Active_Ingredient":"selpercatinib","Approved_Indication":"the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.","Company_name":"Eli Lilly and Company","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.","Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020. On May 29, 2024, the FDA granted accelerated approval for this indication to pediatric patients 2 years of age and older.","Efficacy was evaluated in LIBRETTO-531 (NCT04211337), a randomized, multicenter, open-label study in adults and adolescents with advanced or metastatic RET-mutant MTC. Patients were randomized (2:1) to receive either selpercatinib (160 mg twice daily) or physicians\u2019 choice of cabozantinib (140 mg once daily) or vandetanib (300 mg once daily). Patients were stratified based on RET mutation (M918T vs. other) and intended treatment if randomized to the control arm (cabozantinib vs. vandetanib). ","The main efficacy outcome measure was progression-free survival (PFS), as determined by a blinded independent review committee according to RECIST v1.1. Median PFS was not reached (NR) (95% CI: not evaluable [NE], NE) in the selpercatinib arm and 16.8 months (95% CI: 12.2, 25.1) in the cabozantinib\/vandetanib arm (Hazard Ratio 0.280 [95% CI: 0.165, 0.475] p-value <0.0001). The clinical benefit of selpercatinib was supported by a pre-specified analysis of patient-reported comparative side effect impact; patients in the selpercatinib arm reported less time with severe side effect bother than those receiving cabozantinib or vandetanib.","The most common adverse reactions (\u226525%) were hypertension, edema, dry mouth, fatigue, and diarrhea. The most common Grade 3 or 4 laboratory abnormalities (\u22655%) were decreased lymphocytes, increased alanine aminotransferase (ALT), decreased neutrophils, increased alkaline phosphatase (ALP), increased blood creatinine, decreased calcium, and increased aspartate aminotransferase (AST).","The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area and is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information."],"Efficacy and Safety":null,"Broad_Tumor":"Thyroid cancer","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-medullary-thyroid-cancer-ret-mutation"},{"pdf_link":"Study_302.pdf","index":36,"AA_Date":"2024-09-25","Drug_Name":"Tagrisso (osimertinib)","Brand_Name":"Tagrisso","Active_Ingredient":"osimertinib","Approved_Indication":"the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","Company_name":"AstraZeneca Pharmaceuticals","Relevant Expedited Programs":"Priority Review","Approval_Details":["On September 25, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","Full prescribing information for Tagrisso will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression free survival (PFS) as assessed by blinded independent central review. Additional efficacy outcome measures included overall survival (OS). Osimertinib demonstrated a statistically significant improvement in PFS compared to placebo with a hazard ratio of 0.16 (95% CI: 0.10, 0.24; p-value <0.001). The median PFS was 39.1 months (95% CI: 31.5, not estimable [NE]) in the osimertinib arm and 5.6 months (95% CI: 3.7, 7.4) in the placebo arm.","While OS results were immature at the current analysis, with 36% of pre-specified deaths for the final analysis reported, no trend towards a detriment was observed.","The most common adverse reactions, including laboratory abnormalities (\u226520%), were lymphopenia, leukopenia, interstitial lung disease\/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough, and COVID-19 infection.","The recommended osimertinib dose is 80 mg once daily, with or without food, until disease progression or unacceptable toxicity.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland\u2019s Swissmedic. The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"EGFR exon 19 deletions or exon 21 L858R mutations, EGFR Exon 19","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer"},{"pdf_link":"Study_222.pdf","index":37,"AA_Date":"2024-09-20","Drug_Name":"Sarclisa (isatuximab-irfc)","Brand_Name":"Sarclisa","Active_Ingredient":"isatuximab-irfc","Approved_Indication":"the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).","Company_name":"Sanofi-Aventis U.S. LLC","Relevant Expedited Programs":"Orphan Drug Designation;Priority Review","Approval_Details":["On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).","Full prescribing information for Sarclisa will be posted on Drugs@FDA."],"Efficacy and Safety":["The main efficacy outcome measure was progression-free survival (PFS) as assessed by an independent review committee based on International Myeloma Working Group criteria. IMROZ demonstrated an improvement in PFS in the Isa-VRd arm with a 40% reduction in risk of disease progression or death (hazard ratio 0.60 [95% CI: 0.44, 0.81]; p-value 0.0009); the median PFS was not reached (NR) (95% CI: NR, NR) in the Isa-VRd arm and was 54.3 months (95% CI: 45.2, NR) in the VRd arm.","The most common adverse reactions (\u226520%) were upper respiratory tract infection, diarrhea, fatigue, peripheral sensory neuropathy, pneumonia, musculoskeletal pain, cataract, constipation, peripheral edema, rash, infusion-related reaction, insomnia, and COVID-19 infection.","The recommended isatuximab-irfc dose is 10 mg\/kg actual body weight administered as an intravenous infusion. See the prescribing information for the dosage recommendations for the other drugs.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Multiple myeloma","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-isatuximab-irfc-bortezomib-lenalidomide-and-dexamethasone-newly-diagnosed-multiple"},{"pdf_link":"Study_221.pdf","index":38,"AA_Date":"2024-09-19","Drug_Name":"Rybrevant (amivantamab-vmjw)","Brand_Name":"Rybrevant","Active_Ingredient":"amivantamab-vmjw","Approved_Indication":"the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.","Company_name":"Janssen Biotech, Inc.","Relevant Expedited Programs":"","Approval_Details":["On September 19, 2024, the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.","Full prescribing information for Rybrevant will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) for the comparison between amivantamab + CP and CP. Overall response rate (ORR) per BICR and overall survival (OS) were key secondary outcome measures. Median PFS was 6.3 months (95% CI: 5.6, 8.4) in the amivantamab + CP arm and 4.2 months (95% CI: 4.0, 4.4) in the CP arm (hazard ratio 0.48 [95% CI: 0.36, 0.64], p-value<0.0001). The confirmed ORR was 53% (95% CI: 44, 62) in the amivantamab + CP arm and 29% (95% CI: 23, 35) in the CP arm (p-value<0.0001).","At the prespecified second interim analysis of OS, with 85% of the deaths needed for the final analysis, there was no statistically significant difference in OS. The stratified OS hazard ratio was 0.73 (95% CI: 0.54, 0.99).","The most common adverse reactions (\u226520%) were rash, infusion-related reactions, fatigue, nail toxicity, nausea, constipation, edema, stomatitis, decreased appetite, musculoskeletal pain, vomiting, and COVID-19 infection.","The recommended amivantamab-vmjw dose is based on baseline body weight. See the prescribing information for specific dosage information.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), and Health Canada. The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, Epidermal growth factor receptor (EGFR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19"},{"pdf_link":"Study_200.pdf","index":39,"AA_Date":"2024-09-17","Drug_Name":"Keytruda (pembrolizumab)","Brand_Name":"Keytruda","Active_Ingredient":"pembrolizumab","Approved_Indication":"the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).","Company_name":"Merck","Relevant Expedited Programs":"Priority Review","Approval_Details":["On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).","Full prescribing information for Keytruda will be posted on Drugs@FDA. "],"Efficacy and Safety":["The main efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR), as assessed by blinded independent central review, according to modified RECIST 1.1 for mesothelioma. The trial demonstrated a statistically significant improvement in OS for patients treated with pembrolizumab with chemotherapy compared to those who received chemotherapy alone. Median OS was 17.3 months (95% CI: 14.4, 21.3) versus 16.1 months (95% CI: 13.1, 18.2) (hazard ratio [HR] 0.79 [95% CI: 0.64, 0.98]; p=0.0162). \u00a0","Median PFS was 7.1 months (95% CI: 6.9, 8.1) vs 7.1 months (95% CI: 6.8, 7.7) in pembrolizumab plus chemotherapy and the chemotherapy alone arm, respectively (HR 0.80 [95% CI: 0.65, 0.99]; p=0.0194). Confirmed ORR was 52% (95% CI: 45.5, 59.0) in the pembrolizumab plus chemotherapy arm and 29% (95% CI: 23.0, 35.4) in the chemotherapy alone arm. Median DoR was 6.9 months (95% CI: 5.8, 8.3) and 6.8 months (95% CI: 5.5, 8.5), respectively.","Adverse reactions occurring in patients with MPM were similar to those receiving pembrolizumab with pemetrexed and platinum chemotherapy. See the prescribing information for complete details.","The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity for up to 2 years.","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA) and Health Canada. The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Malignant pleural mesothelioma","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural"},{"pdf_link":"Study_52.pdf","index":41,"AA_Date":"2024-09-12","Drug_Name":"Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)","Brand_Name":"Tecentriq Hybreza","Active_Ingredient":"atezolizumab and hyaluronidase-tqjs","Approved_Indication":"the Food and Drug Administration approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.), including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS). See the prescribing information for the specific indications.","Company_name":"Hybreza, Genentech, Inc.","Relevant Expedited Programs":"","Approval_Details":["On September 12, 2024, the Food and Drug Administration approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.), including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS). See the prescribing information for the specific indications.","Full prescribing information for Tecentriq Hybreza will be posted on Drugs@FDA. "],"Efficacy and Safety":["The primary outcome measure was atezolizumab exposure, with coprimary pharmacokinetic (PK) endpoints of Cycle 1 Ctrough and AUC0-21days. Additional descriptive efficacy outcome measures were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The geometric mean ratio (GMR) (90% CI) of subcutaneous atezolizumab and intravenous atezolizumab for Cycle 1 Ctrough was 1.05 (0.88, 1.24) and AUC0-21days was 0.87 (0.83, 0.92), which met the lower limit of the GMR (90% CI) above the pre-specified threshold of 0.8 for comparability. No notable differences in ORR, PFS or OS were observed between the different formulations. The confirmed ORR was 9% (95% CI: 5, 13) in the subcutaneous atezolizumab and hyaluronidase-tqjs arm and 8% (95% CI: 4, 14) in the intravenous atezolizumab arm.","The most common adverse reactions of any grade (\u2265 10%) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.","The recommended dosage is one 15 mL injection (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered subcutaneously in the thigh over approximately 7 minutes every 3 weeks.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. \u00a0"],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection"},{"pdf_link":"Study_237.pdf","index":42,"AA_Date":"2024-08-19","Drug_Name":"Lazcluze (lazertinib)","Brand_Name":"Lazcluze","Active_Ingredient":"lazertinib","Approved_Indication":"the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","Company_name":"Janssen Biotech, Inc.","Relevant Expedited Programs":"Priority Review","Approval_Details":["On August 19, 2024, the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","Full prescribing information for Lazcluze and Rybrevant will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) for the comparison between lazertinib with amivantamab and osimertinib. Overall survival (OS) was a key secondary outcome measure. Lazertinib with amivantamab demonstrated a statistically significant improvement in PFS compared to osimertinib with a hazard ratio of 0.70 (95% confidence interval [CI]: 0.58, 0.85; p-value=0.0002). The median PFS was 23.7 months (95% CI: 19.1, 27.7) in the lazertinib with amivantamab arm and 16.6 months (95% CI: 14.8, 18.5) in the osimertinib arm.","While OS results were immature at the current analysis, with 55% of pre-specified deaths for the final analysis reported, no trend towards a detriment was observed.","The most common adverse reactions (\u226520%) were rash, nail toxicity, infusion-related reactions (amivantamab), musculoskeletal pain, edema, stomatitis, venous thromboembolism, paresthesia, fatigue, diarrhea, constipation, COVID-19 infection, hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity. A serious safety signal of venous thromboembolic events (VTE) was observed with lazertinib in combination with amivantamab and prophylactic anticoagulation should be administered for the first four months of therapy.","The recommended lazertinib dose is 240 mg orally once daily administered in combination with amivantamab with or without food. The recommended amivantamab dose is based on baseline body weight. See the prescribing information for specific dosing information.","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Switzerland\u2019s Swissmedic, and United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, Epidermal growth factor receptor (EGFR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer"},{"pdf_link":"Study_1.pdf","index":43,"AA_Date":"2024-08-15","Drug_Name":"Imfinzi (durvalumab)","Brand_Name":"Imfinzi","Active_Ingredient":"durvalumab","Approved_Indication":"the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors \u2265 4 cm and\/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.","Company_name":"AstraZeneca","Relevant Expedited Programs":"","Approval_Details":["On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors \u2265 4 cm and\/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.","Full prescribing information for Imfinzi will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measures were event-free survival (EFS) by blinded independent central review assessment and pathological complete response (pCR) by blinded central pathology review. Median EFS was not reached (95% CI: 31.9, not estimable [NE]) in the durvalumab arm and 25.9 months (95% CI: 18.9, NE) in the placebo arm (hazard ratio 0.68 [95% CI: 0.53, 0.88]; p-value=0.0039). The pCR rate was 17% (95% CI: 13, 21) and 4.3% (95% CI: 2.5, 7) in the durvalumab and placebo arms, respectively. \u00a0At the time of the prespecified interim analyses, overall survival (OS) was not formally tested for statistical significance; however, a descriptive analysis revealed no clear detriment.","The most common adverse reactions (\u226520%) were anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash. Of the patients who received neoadjuvant durvalumab, 1.7% were unable to receive surgery due to adverse reactions compared with 1% in the placebo arm.\u00a0","For patients with a body weight of \u2265 30 kg, the recommended durvalumab dosage is 1,500 mg every 3 weeks (neoadjuvant treatment) and every 4 weeks (adjuvant treatment). For patients with a body weight of < 30 kg, the recommended durvalumab dosage is 20 mg\/kg. Durvalumab should be administered prior to chemotherapy when administered on the same day.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Small cell lung cancer (SCLC)","Biomarker":"Epidermal growth factor receptor (EGFR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer"},{"pdf_link":"Study_289.pdf","index":44,"AA_Date":"2024-08-14","Drug_Name":"Niktimvo (axatilimab-csfr)","Brand_Name":"Niktimvo","Active_Ingredient":"axatilimab-csfr","Approved_Indication":"the Food and Drug Administration approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.","Company_name":"Incyte Corporation","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On August 14, 2024, the Food and Drug Administration approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.","Full prescribing information for Niktimvo will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measure was overall response rate (ORR) through Cycle 7 Day 1, where overall response included complete response or partial response according to the 2014 NIH Consensus Development Project on Response Criteria. ORR was 75% (95% CI: 64, 84) in the 79 patients treated with the recommended dosage. The median time to first response was 1.5 months (range: 0.9 to 5.1). The median duration of response, calculated from first response to progression, death, or new systemic therapies for chronic GVHD, was 1.9 months (95% CI: 1.6, 3.5). In patients who achieved response, no death or new systemic therapy initiation occurred in 60% (95% CI: 43, 74) of patients for at least 12 months since response.","The most common (\u2265 15%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase (AST), infection (pathogen unspecified), increased alanine aminotransferase (ALT), decreased phosphate, decreased hemoglobin, viral infection, increased gamma glutamyl transferase (GGT), musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased creatine phosphokinase (CPK), increased alkaline phosphatase (ALP), nausea, headache, diarrhea, cough, bacterial infection, pyrexia, and dyspnea.","The recommended axatilimab-csfr dose in patients who weigh at least 40 kg is 0.3\u00a0mg\/kg, up to a maximum dose of 35 mg, as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease"},{"pdf_link":"Study_209.pdf","index":45,"AA_Date":"2024-08-06","Drug_Name":"Voranigo (vorasidenib)","Brand_Name":"Voranigo","Active_Ingredient":"vorasidenib","Approved_Indication":"the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.","Company_name":"Servier Pharmaceuticals LLC","Relevant Expedited Programs":"Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.","Full prescribing information for Voranigo will be posted on Drugs@FDA. ","This is the first approval by the FDA of a systemic therapy for patients with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) using a blinded independent review committee per modified Response Assessment in Neuro-Oncology for Low Grade Glioma (RANO-LGG) criteria. An additional efficacy outcome measure was time to next intervention. The hazard ratio for PFS was 0.39 (95% CI: 0.27, 0.56), p-value <0.0001. The median time to next intervention was not reached for the vorasidenib arm and was 17.8 months for the placebo arm (HR=0.26; 95% CI: [0.15, 0.43], p\u00a0<0.0001).","The most common (\u226515%) adverse reactions were fatigue, headache, COVID-19 infection, musculoskeletal pain, diarrhea, nausea, and seizure. The most common Grade 3 or 4 laboratory abnormalities (>2%) were increased alanine aminotransferase, increased aspartate aminotransferase, GGT increased, and decreased neutrophils.","The recommended vorasidenib dose in adult patients is 40 mg orally once daily until disease progression or unacceptable toxicity. The recommended vorasidenib dose in pediatric patients 12 years and older is based on body weight:","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Switzerland\u2019s Swissmedic, and Israel\u2019s Ministry of Health (IMoH). The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. \u00a0"],"Broad_Tumor":"","Biomarker":"IDH1, IDH1 or IDH2 mutation, Isocitrate dehydrogenase-2, Isocitrate dehydrogenase-1","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation"},{"pdf_link":"Study_324.pdf","index":46,"AA_Date":"2024-08-02","Drug_Name":"TECELRA (afamitresgene auleucel)","Brand_Name":"TECELRA","Active_Ingredient":"afamitresgene auleucel","Approved_Indication":"the Food and Drug Administration granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.","Company_name":"Adaptimmune, LLC","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On August 2, 2024, the Food and Drug Administration granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.","Full prescribing information for TECELRA will be posted at 2024 Biological License Application Approvals.","Efficacy was evaluated in SPEARHEAD-1, Cohort 1, a multicenter, single-arm, open-label clinical trial that enrolled HLA-A*02:01-03 and 06 allele positive patients with inoperable or metastatic synovial sarcoma who had received prior systemic therapy with either doxorubicin and\/or ifosfamide and whose tumor expressed the MAGE-A4 tumor antigen. Patients received lymphodepleting chemotherapy with fludarabine and cyclophosphamide.","Fifty-two patients with synovial sarcoma were enrolled and underwent leukapheresis, eight of whom did not receive afamitresgene autoleucel due to death (n=3), loss of eligibility prior to lymphodepleting chemotherapy (n=3), withdrawal by patient (n=1), and investigator decision (n=1). Forty-five patients received lymphodepletion and one patient withdrew consent before treatment, for a total of 44 patients who received a single infusion of afamitresgene autoleucel.","The main efficacy outcome measure was overall response rate (ORR) according to RECIST v1.1 evaluated by independent review, supported by duration of response (DOR). ORR was 43.2% (95% Confidence Interval [CI]: 28.4, 59.0). The median time to response was 4.9 weeks (95% CI: 4.4 weeks, 8 weeks). The median DOR was 6 months (95% CI: 4.6, not reached). Among patients who were responsive to the treatment, 45.6% and 39.0% had a duration of response greater than or equal to 6 months and 12 months, respectively.","The prescribing information includes a Boxed Warning for serious or fatal cytokine release syndrome (CRS), which may be severe or life-threatening.","The most common nonlaboratory adverse reactions (\u2265 20%) were cytokine release syndrome, nausea, vomiting, fatigue, infections, pyrexia, constipation, dyspnea, abdominal pain, non-cardiac chest pain, decreased appetite, tachycardia, back pain, hypotension, diarrhea, and edema. The most common grade 3 or 4 laboratory abnormalities (\u2265 20%) were lymphocyte count decreased, neutrophil count decreased, white cell blood count decreased, red blood cell decreased, and platelet count decreased.","The recommended afamitresgene autoleucel dose is between 2.68 x 109 to 10 x 109 MAGE-A4 T cell receptor (TCR) positive T cells, administered in one or more infusion bags. Do not use a leukodepleting filter or prophylactic systemic corticosteroids.","This application is approved under the accelerated approval pathway. To verify the clinical benefit of afamitresgene autoleucel, the FDA and the sponsor agreed upon a postmarketing requirement for an ongoing study in adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted Regenerative Medicine Advanced Therapy, priority review, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products regulated by the Center for Biologics Evaluation and Research, healthcare professionals may email OTPRPMS@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","08\/02\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"Melanoma","Biomarker":"HLA-A*02:01, HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen","url_name":"\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma"},{"pdf_link":"Study_273.pdf","index":8,"AA_Date":"2024-08-02","Drug_Name":"Tecelra (afamitresgene autoleucel)","Brand_Name":"Tecelra","Active_Ingredient":"afamitresgene autoleucel","Approved_Indication":"the Food and Drug Administration granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.","Company_name":"Adaptimmune, LLC","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On August 2, 2024, the Food and Drug Administration granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.","Full prescribing information for TECELRA will be posted at 2024 Biological License Application Approvals.","Efficacy was evaluated in SPEARHEAD-1, Cohort 1, a multicenter, single-arm, open-label clinical trial that enrolled HLA-A*02:01-03 and 06 allele positive patients with inoperable or metastatic synovial sarcoma who had received prior systemic therapy with either doxorubicin and\/or ifosfamide and whose tumor expressed the MAGE-A4 tumor antigen. Patients received lymphodepleting chemotherapy with fludarabine and cyclophosphamide.","Fifty-two patients with synovial sarcoma were enrolled and underwent leukapheresis, eight of whom did not receive afamitresgene autoleucel due to death (n=3), loss of eligibility prior to lymphodepleting chemotherapy (n=3), withdrawal by patient (n=1), and investigator decision (n=1). Forty-five patients received lymphodepletion and one patient withdrew consent before treatment, for a total of 44 patients who received a single infusion of afamitresgene autoleucel.","The main efficacy outcome measure was overall response rate (ORR) according to RECIST v1.1 evaluated by independent review, supported by duration of response (DOR). ORR was 43.2% (95% Confidence Interval [CI]: 28.4, 59.0). The median time to response was 4.9 weeks (95% CI: 4.4 weeks, 8 weeks). The median DOR was 6 months (95% CI: 4.6, not reached). Among patients who were responsive to the treatment, 45.6% and 39.0% had a duration of response greater than or equal to 6 months and 12 months, respectively.","The prescribing information includes a Boxed Warning for serious or fatal cytokine release syndrome (CRS), which may be severe or life-threatening.","The most common nonlaboratory adverse reactions (\u2265 20%) were cytokine release syndrome, nausea, vomiting, fatigue, infections, pyrexia, constipation, dyspnea, abdominal pain, non-cardiac chest pain, decreased appetite, tachycardia, back pain, hypotension, diarrhea, and edema. The most common grade 3 or 4 laboratory abnormalities (\u2265 20%) were lymphocyte count decreased, neutrophil count decreased, white cell blood count decreased, red blood cell decreased, and platelet count decreased.","The recommended afamitresgene autoleucel dose is between 2.68 x 109 to 10 x 109 MAGE-A4 T cell receptor (TCR) positive T cells, administered in one or more infusion bags. Do not use a leukodepleting filter or prophylactic systemic corticosteroids.","This application is approved under the accelerated approval pathway. To verify the clinical benefit of afamitresgene autoleucel, the FDA and the sponsor agreed upon a postmarketing requirement for an ongoing study in adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted Regenerative Medicine Advanced Therapy, priority review, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products regulated by the Center for Biologics Evaluation and Research, healthcare professionals may email OTPRPMS@fda.hhs.gov.","Follow the Oncology Center of Excellence on X: @FDAOncology.","08\/02\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"Melanoma","Biomarker":"HLA-A*02:01, HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma"},{"pdf_link":"Study_140.pdf","index":47,"AA_Date":"2024-08-01","Drug_Name":"Jemperli (dostarlimab-gxly)","Brand_Name":"Jemperli","Active_Ingredient":"dostarlimab-gxly","Approved_Indication":"the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC). Dostarlimab-gxly previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent EC that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).","Company_name":"","Relevant Expedited Programs":"Priority Review","Approval_Details":["On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC). Dostarlimab-gxly previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent EC that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).","Full prescribing information for Jemperli will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were progression-free survival (PFS) (investigator-assessed using RECIST v1.1) in the dMMR\/MSI-H and overall populations, and overall survival (OS) in the overall population. In the overall population, a statistically significant OS improvement was observed with a median OS of 44.6 months (95% CI: 32.6, not reached) and 28.2 months (95% CI: 22.1, 35.6) in the dostarlimab-gxly and placebo arms, respectively (Hazard Ratio=0.69 [95% CI: 0.54, 0.89]; 1-sided p-value=0.002). Median PFS in the overall population was 11.8 months (95% CI: 9.6, 17.1) and 7.9 months (95% CI: 7.6, 9.5) in the dostarlimab-gxly and placebo arms, respectively (Hazard Ratio=0.64 [95% CI: 0.51, 0.80]; 1-sided p-value <0.0001).","The most common adverse reactions (\u226520%) with dostarlimab-gxly with carboplatin and paclitaxel were anemia, increased creatinine, peripheral neuropathy, decreased white blood cell count, fatigue, nausea, alopecia, low platelets, increased glucose, lymphopenia, neutropenia, liver function test abnormalities, arthralgia, rash, constipation, diarrhea, decreased albumin, abdominal pain, dyspnea, decreased appetite, increased amylase, urinary tract infection and vomiting. Immune-mediated adverse reactions with dostarlimab-gxly were similar to those previously reported for dostarlimab-gxly. See dostarlimab-gxly full prescribing information for complete adverse reactions.","The recommended dostarlimab-gxly dose is 500 mg every 3 weeks for 6 cycles with carboplatin and paclitaxel, followed by 1,000 mg monotherapy every 6 weeks until disease progression or unacceptable toxicity, or up to 3 years. Dostarlimab-gxly should be administered before chemotherapy when administered on the same day.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment. The FDA approved this application 3 weeks ahead of the FDA goal date."],"Broad_Tumor":"Endometrial cancer (EC)","Biomarker":"Microsatellite instability-high (MSI-H), Microsatellite instability, Mismatch repair deficient, Mismatch repair deficient (dMMR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy"},{"pdf_link":"Study_118.pdf","index":48,"AA_Date":"2024-07-30","Drug_Name":"Darzalex Faspro (daratumumab and hyaluronidase-fihj)","Brand_Name":"Darzalex Faspro","Active_Ingredient":"daratumumab and hyaluronidase-fihj","Approved_Indication":"the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).","Company_name":"Faspro, Janssen Research & Development, LLC","Relevant Expedited Programs":"Priority Review","Approval_Details":["On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).","Full prescribing information for Darzalex Faspro will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS) as assessed by an independent review committee based on International Myeloma Working Group (IMWG) response criteria. PERSEUS demonstrated an improvement in PFS in the Darzalex Faspro-VRd arm as compared to the VRd arm; the median PFS had not been reached in either arm. Treatment with Darzalex Faspro-VRd resulted in a reduction in the risk of disease progression or death by 60% compared to VRd alone (HR [95% CI]: 0.40 [0.29, 0.57]; p-value\u00a0<\u00a00.0001).","The most common adverse reactions (\u226520%) were peripheral neuropathy, fatigue, edema, pyrexia, upper respiratory infection, constipation, diarrhea, musculoskeletal pain, insomnia, and rash.","The recommended Darzalex Faspro dose is 1,800 mg\/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase). See the prescribing information for the dosage recommendations for the other drugs.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Multiple myeloma","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-multiple"},{"pdf_link":"Study_0.pdf","index":10,"AA_Date":"2024-06-26","Drug_Name":"Epkinly (epcoritamab-bysp)","Brand_Name":"Epkinly","Active_Ingredient":"epcoritamab-bysp","Approved_Indication":"the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.","Company_name":"Genmab US, Inc.","Relevant Expedited Programs":"Accelerated Approval;Priority Review","Approval_Details":["On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.","Full prescribing information for Epkinly will be posted on Drugs@FDA.","Efficacy and safety were evaluated in EPCORE NHL-1 (Study GCT3013-01; NCT03625037), an open-label, multi-cohort, multicenter, single-arm trial that included 127 patients with relapsed or refractory FL after at least 2 lines of systemic therapy. The primary efficacy and safety were based on 127 patients who received a 2 step-up dosing regimen. A separate dose optimization cohort of 86 patients evaluated the recommended 3-step up dosage schedule for cytokine release syndrome (CRS) mitigation.","The main efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), determined by an Independent Review Committee using the Lugano 2014 criteria. In the 127 patients in the primary efficacy population, the ORR was 82% (95% CI: 74.1, 88.2) with 60% achieving complete responses. With an estimated median follow-up of 14.8 months among responders, the estimated median DOR was not reached (NR) (95% CI: 13.7, NR). The 12-month Kaplan-Meier estimate for DOR was 68.4% (95% CI: 57.6%, 77.0%). Efficacy was similar in the 86 patients who received the 3 step-up dosage schedule.","The prescribing information includes a Boxed Warning for serious or fatal cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS). Warnings and Precautions include serious infections and cytopenias. ICANS occurred in 6.0%, and serious infections in 40%. Among 86 patients with relapsed or refractory follicular lymphoma who received the recommended 3-step dosage regimen, CRS occurred in 49%, all events were grades 1 (45%) or 2 (9%).","The most common adverse reactions (\u226520%) were injection site reactions, cytokine release syndrome, COVID-19 infection, fatigue, upper respiratory tract infection, musculoskeletal pain, rash, diarrhea, pyrexia, cough, and headache. The most common Grade 3 to 4 laboratory abnormalities (\u226510%) were decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and decreased hemoglobin.","The recommended regimen consists of epcoritamab-bysp administered subcutaneously in 28-day cycles until disease progression or unacceptable toxicity. The recommended dose is a 3 step-up dosage schedule in Cycle 1 (0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22), Cycle 2 and 3 (48 mg on Days 1, 8, 15, and 22), Cycles 4 to 9 (48 mg on Days 1 and 15), and Cycle 10 and beyond (48 mg on Day 1).","This application is approved under the accelerated approval pathway. To verify the clinical benefit of epcoritamab-bysp, a Phase 3 randomized trial (NCT05409066) is ongoing and close to fully enrolled (95%), which is evaluating rituximab and lenalidomide alone or in combination with epcoritamab-bysp in patients with relapsed or refractory FL.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review and breakthrough designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X @FDAOncology.","06\/26\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"Marginal zone lymphoma (MZL), Follicular lymphoma (FL)","Biomarker":"CD20","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma"},{"pdf_link":"Study_295.pdf","index":9,"AA_Date":"2024-06-21","Drug_Name":"Krazati (adagrasib)","Brand_Name":"Krazati","Active_Ingredient":"adagrasib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.","Company_name":"Mirati Therapeutics, Inc.","Relevant Expedited Programs":"Accelerated Approval;Breakthrough Therapy Designation;Priority Review","Approval_Details":["On June 21, 2024, the Food and Drug Administration granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.","Full prescribing information for Krazati will be posted on Drugs@FDA. "],"Efficacy and Safety":["The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) according to RECIST v1.1 assessed by blinded independent central review. In the 94 enrolled patients, ORR was 34% (95% CI: 25%, 45%), all responses were partial responses, and median DOR was 5.8 months (95% CI: 4.2, 7.6). Thirty-one percent of responding patients had a DOR of at least 6 months.","The most common adverse reactions (\u226520%) were rash, nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, headache, dry skin, abdominal pain, decreased appetite, edema, anemia, cough, dizziness, constipation, and peripheral neuropathy.","The recommended adagrasib dose is 600 mg orally twice daily until disease progression or unacceptable toxicity. Refer to the cetuximab prescribing information for cetuximab dosage information.","This application was granted priority review and breakthrough therapy designation. FDA expedited programs are described in the\u00a0Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics."],"Broad_Tumor":"Colorectal cancer (CRC)","Biomarker":"KRAS G12C","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer"},{"pdf_link":"Study_214.pdf","index":51,"AA_Date":"2024-06-17","Drug_Name":"Keytruda (pembrolizumab)","Brand_Name":"Keytruda","Active_Ingredient":"pembrolizumab","Approved_Indication":"the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.","Company_name":"Merck","Relevant Expedited Programs":"Priority Review","Approval_Details":["On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.","Full prescribing information for Keytruda will be posted on Drugs@FDA.","Efficacy was evaluated in KEYNOTE-868\/NRG-GY018 (NCT03914612), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 810 patients with advanced or recurrent endometrial carcinoma. The trial included two separate cohorts based on mismatch repair (MMR) status: 222 patients in the mismatch repair deficient (dMMR) cohort, and 588 patients in the mismatch repair (pMMR) proficient cohort. Patients were randomized (1:1) to one of the following treatment arms:","Randomization was stratified according to MMR status, ECOG performance status (0 or 1 vs. 2), and prior adjuvant chemotherapy.","The major efficacy outcome measure was progression-free survival (PFS), assessed by the investigator according to RECIST 1.1. In the dMMR cohort, median PFS was not reached (NR) (95% CI: 30.7, NR) in the pembrolizumab and chemotherapy arm and 6.5 months (95% CI: 6.4, 8.7) in the placebo and chemotherapy arm (Hazard ratio [HR] 0.30 [95% CI: 0.19, 0.48]; p-value <0.0001). In the pMMR cohort, median PFS was 11.1 months (95% CI: 8.7, 13.5) in the pembrolizumab and chemotherapy arm and 8.5 months (95% CI: 7.2, 8.8) for those receiving placebo and chemotherapy arm (HR 0.60 [95% CI: 0.46, 0.78; p-value <0.0001).","Adverse reactions associated with pembrolizumab and chemotherapy were generally similar to those previously reported for pembrolizumab or chemotherapy with the exception of a higher incidence of rash. See the prescribing information for complete adverse reactions.","The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months.","This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada (HC), and Israel\u2019s Ministry of Health (IMoH). The application reviews are ongoing at the other regulatory agencies.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X @FDAOncology.","06\/17\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"Endometrial carcinoma","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemotherapy-primary-advanced-or-recurrent-endometrial-carcinoma"},{"pdf_link":"Study_310.pdf","index":52,"AA_Date":"2024-06-14","Drug_Name":"Blincyto (blinatumomab)","Brand_Name":"Blincyto","Active_Ingredient":"blinatumomab","Approved_Indication":"the Food and Drug Administration approved blinatumomab (Blincyto, Amgen Inc.) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy.","Company_name":"Amgen Inc.","Relevant Expedited Programs":"Orphan Drug Designation;Priority Review","Approval_Details":["On June 14, 2024, the Food and Drug Administration approved blinatumomab (Blincyto, Amgen Inc.) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy.","Full prescribing information for Blincyto will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measure was overall survival (OS). The 3-year OS was 84.8% (95% CI: 76.3, 90.4) and 69% (95% CI: 58.7, 77.2) in the blinatumomab and chemotherapy arms, respectively. The hazard ratio [HR] for OS was 0.42 [95% CI: 0.24, 0.75] p-value 0.003). In a later analysis with a median follow-up of 4.5 years, the 5-year OS was 82.4 % [95% CI (73.7, 88.4)] in the blinatumomab arm and 62.5 % [95% CI (52.0, 71.3)] in the chemotherapy arm. The hazard ratio was 0.44 [95% CI (0.25, 0.76)].","Efficacy also was evaluated in Study 20120215 (NCT02393859), a randomized, controlled, open-label, multicenter trial. Pediatric and young adult patients with Ph-negative BCP ALL were randomized 1:1 to receive blinatumomab or the IntReALLHR2010 HC3 intensive combination chemotherapy as the third consolidation cycle. Randomization was stratified by age, minimal residual disease status at the end of induction based on local assessment, and bone marrow status at the end of the second block of consolidation chemotherapy. There were 54 patients randomized to the blinatumomab arm and 57 to the chemotherapy arm.","The major efficacy outcome measures were OS and relapse-free survival (RFS). The 5\u2011year OS was 78.4% (95% CI: 64.2, 87.4) and 41.4% (95% CI: 26.3, 55.9) in the blinatumomab and chemotherapy arms, respectively (OS HR 0.35 [95% CI: 0.17, 0.70]). The 5-year RFS was 61.1% (95% CI: 46.3, 72.9) and 27.6% (95% CI: 16.2, 40.3) in the blinatumomab and chemotherapy arms, respectively (RFS HR 0.38 [95% CI: 0.22, 0.66].","In Study E1910, the most common adverse reactions (\u226520%) in the blinatumomab arm were neutropenia, thrombocytopenia, anemia, leukopenia, headache, infection, nausea, lymphopenia, diarrhea, musculoskeletal pain, and tremor. In Study 20120215, the most common adverse reactions (\u226520%) in the blinatumomab arm were pyrexia, nausea, headache, rash, hypogammaglobulinemia, and anemia.","See the full prescribing information for the recommended dose by patient weight and schedule.","This review was conducted under\u00a0Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Brazilian Health Regulatory Agency (ANVISA), Health Canada (HC), Switzerland\u2019s Swissmedic (SMC), and United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies."],"Broad_Tumor":"B-cell precursor acute lymphoblastic leukemia (BCP ALL)","Biomarker":"CD19-positive Philadelphia chromosome-negative, Philadelphia Chromosome, CD19","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell"},{"pdf_link":"Study_32.pdf","index":53,"AA_Date":"2024-06-14","Drug_Name":"Imfinzi (durvalumab)","Brand_Name":"Imfinzi","Active_Ingredient":"durvalumab","Approved_Indication":"the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).","Company_name":"AstraZeneca UK Limited","Relevant Expedited Programs":"","Approval_Details":["On June 14, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).","Full prescribing information for Imfinzi will be posted on Drugs@ FDA."],"Efficacy and Safety":["The major efficacy outcome measure was progression-free survival (PFS), determined by investigator assessment using RECIST v1.1.","While a statistically significant improvement in PFS was observed in the overall population for durvalumab with carboplatin plus paclitaxel compared to carboplatin and paclitaxel alone, the improvement in the overall population was primarily attributed to patients with dMMR tumors based on an exploratory analysis by tumor MMR status.","In 95 patients with dMMR tumors, median PFS was not reached (NR) (95% CI: NR, NR) in the durvalumab arm and was 7 months (95% CI: 6.7, 14.8) in the placebo arm (hazard ratio:\u00a0 0.42 [95% CI: 0.22, 0.80]). Overall survival, an additional efficacy outcome measure, was immature at the PFS analysis.","The most common adverse reactions (>25%) with durvalumab in combination with carboplatin and paclitaxel were peripheral neuropathy, musculoskeletal pain, nausea, alopecia, fatigue, abdominal pain, constipation, rash, diarrhea, vomiting, and cough. The prescribing information provides the complete adverse reactions.","The recommended durvalumab dose for patients with a body weight \u2265 30 kg is 1,120 mg with carboplatin plus paclitaxel every 3 weeks for 6 cycles, followed by single- agent durvalumab 1,500 mg every 4 weeks. The recommended durvalumab dose for patients with a body weight of < 30 kg is 15 mg\/kg with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by durvalumab 20 mg\/kg every 4 weeks.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Endometrial cancer (EC)","Biomarker":"Mismatch repair deficient, Mismatch repair deficient (dMMR)","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-chemotherapy-mismatch-repair-deficient-primary-advanced-or-recurrent"},{"pdf_link":"Study_189.pdf","index":11,"AA_Date":"2024-06-13","Drug_Name":"Augtyro (repotrectinib)","Brand_Name":"Augtyro","Active_Ingredient":"repotrectinib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.","Company_name":"Bristol-Myers Squibb Company","Relevant Expedited Programs":"Accelerated Approval;Breakthrough Therapy Designation;Fast Track Desgination;Orphan Drug Designation;Priority Review","Approval_Details":["On June 13, 2024, the Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.","Full prescribing information for Augtyro will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by blinded independent central review. Confirmed ORR in the TKI-na\u00efve group was 58% (95% [confidence internal] CI: 41, 73) and 50% (95% CI: 35, 65) in the TKI-pretreated group. Median DOR was not estimable (NE) (95% CI: NE, NE) in the TKI-na\u00efve group and 9.9 months (95% CI: 7.4, 13.0) in the TKI-pretreated group.","The most common (>20%) adverse reactions were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea.","The recommended repotrectinib dose is 160 mg orally once daily for 14 days, then increased to 160 mg twice daily with or without food, until disease progression or unacceptable toxicity.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Solid tumors","Biomarker":"Neurotrophic tyrosine receptor kinase (NTRK) gene fusion","url_name":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"},{"pdf_link":"Study_139.pdf","index":55,"AA_Date":"2024-06-12","Drug_Name":"Retevmo (selpercatinib)","Brand_Name":"Retevmo","Active_Ingredient":"selpercatinib","Approved_Indication":"the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).","Company_name":"Eli Lilly and Company","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation","Approval_Details":["On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).","Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020.","Full prescribing information for Retevmo will be posted on Drugs@FDA."],"Efficacy and Safety":["The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR). The ORR was 85% (95% CI: 71%, 94%) in the 41 previously treated patients and 96% (95% CI: 79%, 100%) in the 24 systemic therapy na\u00efve patients. Median DOR was 26.7 months (95% CI: 12.1, not evaluable [NE]) in the previously treated patients and NE (95% CI: 42.8, NE) in the systemic therapy na\u00efve patients.","Supportive evidence included ORR and DOR data from 10 pediatric and young adult patients with RET fusion-positive thyroid cancer treated in Study LIBRETTO-121 (J2G-OX-JZJJ; NCT03899792), an international, single-arm, multi-cohort clinical trial of selpercatinib in pediatric and young adult patients with advanced RET-altered solid tumors. The ORR was 60% (95% CI: 26%, 88%), and 83% had an observed duration of response \u2265 12 months.","The most common adverse reactions (\u226525%) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache. The most common Grade 3 or 4 laboratory abnormalities (\u22655%) were decreased lymphocytes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), decreased sodium, and decreased calcium.","The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area. It is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Thyroid cancer","Biomarker":"RET fusion","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer"},{"pdf_link":"Study_169.pdf","index":56,"AA_Date":"2024-06-06","Drug_Name":"Rytelo (imetelstat)","Brand_Name":"Rytelo","Active_Ingredient":"imetelstat","Approved_Indication":"the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).","Company_name":"Geron Corporation","Relevant Expedited Programs":"Orphan Drug Designation","Approval_Details":["On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).","Full prescribing information for Rytelo will be posted here.","Efficacy was evaluated in IMerge (NCT02598661), a randomized (2:1), double-blind, placebo-controlled multicenter trial in 178 patients with MDS. Patients received an intravenous infusion of imetelstat 7.1 mg\/kg or placebo in 28-day treatment cycles until disease progression or unacceptable toxicity. Randomization was stratified by prior red blood cell (RBC) transfusion burden and by International Prognostic Scoring System (IPSS) risk group. All patients received supportive care, which included RBC transfusions.","Efficacy was established after a median follow up time of 19.5 months (range: 1.4 to 36.2) in the imetelstat group and 17.5 months (range: 0.7 to 34.3) in the placebo group based upon the proportion of patients who achieved \u2265 8-week and \u2265 24-week RBC transfusion independence (RBC-TI), defined as the absence of RBC transfusion(s) during any consecutive 8 week period, and during any consecutive 24 week period, respectively, from randomization until the start of subsequent anti-cancer therapy (if any). The rate of \u2265 8-week RBC-TI was 39.8% (95% CI: 30.9, 49.3) in the imetelstat group and 15% (95% CI: 7.1, 26.6) in the placebo group (p-value < 0.001). The rate of \u2265 24-week RBC-TI was 28% (95% CI: 20.1, 37) in the imetelstat group and 3.3% (95% CI: 0.4, 11.5) in the placebo group (p-value < 0.001).","The most common adverse reactions (\u2265 10% with a difference between arms of > 5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia\/myalgia, COVID-19 infections, and headache.","The recommended imetelstat dosage is 7.1 mg\/kg administered as an intravenous infusion over 2 hours every 4 weeks.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This product was granted orphan drug designation.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology.","06\/06\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"Myelodysplastic syndromes (MDS)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent"},{"pdf_link":"Study_282.pdf","index":57,"AA_Date":"2024-05-30","Drug_Name":"Breyanzi (lisocabtagene maraleucel)","Brand_Name":"Breyanzi","Active_Ingredient":"lisocabtagene maraleucel","Approved_Indication":"the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).","Company_name":"Juno Therapeutics, Inc.","Relevant Expedited Programs":"Orphan Drug Designation;Priority Review","Approval_Details":["On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).","Full prescribing information for Breyanzi will be posted here."],"Efficacy and Safety":["Patients received a single dose of lisocabtagene maraleucel 2 to 7 days following the completion of lymphodepleting chemotherapy (fludarabine 30 mg\/m2\/day and cyclophosphamide 300 mg\/m2\/day concurrently for 3 days). The primary efficacy analysis included a total of 68 patients with MCL who received at least 2 prior lines of therapy including a BTKi, had PET-positive disease at study baseline or after bridging therapy, received conforming product in the intended dose range, and had at least 6 months of follow-up from the date of first response.","The main efficacy outcome measure was overall response rate (ORR), defined as percentage of patients with best overall response (BOR) of either complete response (CR) or partial response (PR) after lisocabtagene maraleucel infusion, as determined by an independent review committee (IRC) using 2014 Lugano classification. Other efficacy measures included complete response rate (CRR) and duration of response (DOR), as determined by IRC. The ORR was 85.3% (95% CI: 74.6, 92.7) and the CRR was 67.6% (95% CI: 55.2, 78.5). After a median follow-up of 22.2 months (95% CI: 16.7, 22.8), the median DOR was 13.3 months (95% CI: 6.0, 23.3).","The most common nonlaboratory adverse reactions (\u2265\u00a020%) were cytokine release syndrome (CRS), fatigue, musculoskeletal pain, encephalopathy, edema, headache, and decreased appetite. FDA approved lisocabtagene maraleucel with a Risk Evaluation and Mitigation Strategy due to the risk of fatal or life-threatening CRS and neurologic toxicities.","The recommended lisocabtagene maraleucel dose is 90 to 110 \u00d7 106 CAR-positive viable T cells with a 1:1 ratio of CD4 and CD8 components.","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment."],"Broad_Tumor":"Mantle cell lymphoma (MCL)","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma"},{"pdf_link":"Study_119.pdf","index":58,"AA_Date":"2024-05-29","Drug_Name":"Retevmo (selpercatinib)","Brand_Name":"Retevmo","Active_Ingredient":"selpercatinib","Approved_Indication":"the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following:","Company_name":"Eli Lilly and Company","Relevant Expedited Programs":"Accelerated Approval;Orphan Drug Designation;Priority Review","Approval_Details":["On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following:","This is the first FDA approval of a targeted therapy for pediatric patients < 12 years of age with RET alterations. Selpercatinib was previously granted accelerated approval for the thyroid cancer indications in adults and pediatric patients 12 years of age and older. It also was previously granted accelerated approval for the solid tumor indication in adults.","Full prescribing information for Retevmo will be posted here.","Efficacy in pediatric and young adult patients was evaluated in LIBRETTO-121 (NCT03899792), an international, single-arm, multi-cohort trial. Patients received selpercatinib, 92 mg\/m2 orally twice daily, until disease progression, unacceptable toxicity, or other reason for treatment discontinuation. The primary efficacy population included 25 patients ages 2 to 20 with locally advanced or metastatic RET-activated solid tumors non-responsive to available therapies or with no standard systemic curative therapy available.","The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR). The confirmed ORR (RECIST 1.1), as determined by blinded independent review committee was 48% (95% CI: 28, 69). The median DOR was not reached (95% CI: not evaluable [NE], NE), with 92% of responders remaining in response at 12 months. Durable responses were observed in pediatric and young adult patients with RET-mutant MTC (n=14; ORR 43% [95% CI: 18%, 71%]) and RET fusion-positive thyroid cancer (n=10; ORR 60% [95% CI: 26%, 88%]).","The most common adverse reactions (\u226525%) were musculoskeletal pain, diarrhea, headache, nausea, vomiting, coronavirus infection, abdominal pain, fatigue, pyrexia, and hemorrhage. The most common Grade 3 or 4 laboratory abnormalities (\u22655%) were decreased calcium, decreased hemoglobin, and decreased neutrophils.","The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area. It is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information.","LIBRETTO-121 was conducted as part of a pediatric Written Request (WR) under the Best Pharmaceuticals for Children Act (BPCA).","This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.","This application was granted priority review and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.","Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System or by calling 1-800-FDA-1088.","For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE\u2019s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.","Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology.","06\/17\/2024\n"],"Efficacy and Safety":null,"Broad_Tumor":"","Biomarker":"","url_name":"\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selpercatinib-pediatric-patients-two-years-and-older-ret-altered"}]